Antigens: Substances that are recognized by the immune system and induce an immune reaction.Antigens, CD: Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.Antigens, CD8: Differentiation antigens found on thymocytes and on cytotoxic and suppressor T-lymphocytes. CD8 antigens are members of the immunoglobulin supergene family and are associative recognition elements in MHC (Major Histocompatibility Complex) Class I-restricted interactions.Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Antigens, CD3: Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA).Antigens, Surface: Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.Antigens, Bacterial: Substances elaborated by bacteria that have antigenic activity.Antigens, CD38: A bifunctional enzyme that catalyzes the synthesis and HYDROLYSIS of CYCLIC ADP-RIBOSE (cADPR) from NAD+ to ADP-RIBOSE. It is a cell surface molecule which is predominantly expressed on LYMPHOID CELLS and MYELOID CELLS.Antigens, CD34: Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.Antigens, CD19: Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.Antigens, CD40: A member of the tumor necrosis factor receptor superfamily with specificity for CD40 LIGAND. It is found on mature B-LYMPHOCYTES and some EPITHELIAL CELLS, lymphoid DENDRITIC CELLS. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centers. Mutations of the gene for CD40 antigen result in HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 3. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.CD40 Ligand: A membrane glycoprotein and differentiation antigen expressed on the surface of T-cells that binds to CD40 ANTIGENS on B-LYMPHOCYTES and induces their proliferation. Mutation of the gene for CD40 ligand is a cause of HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 1.Antigens, CD20: Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.Antigens, Viral: Substances elaborated by viruses that have antigenic activity.Antigens, CD28: Costimulatory T-LYMPHOCYTE receptors that have specificity for CD80 ANTIGEN and CD86 ANTIGEN. Activation of this receptor results in increased T-cell proliferation, cytokine production and promotion of T-cell survival.Antigens, CD44: Acidic sulfated integral membrane glycoproteins expressed in several alternatively spliced and variable glycosylated forms on a wide variety of cell types including mature T-cells, B-cells, medullary thymocytes, granulocytes, macrophages, erythrocytes, and fibroblasts. CD44 antigens are the principle cell surface receptors for hyaluronate and this interaction mediates binding of lymphocytes to high endothelial venules. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)Antigens, CD7: Differentiation antigens expressed on pluripotential hematopoietic cells, most human thymocytes, and a major subset of peripheral blood T-lymphocytes. They have been implicated in integrin-mediated cellular adhesion and as signalling receptors on T-cells.Antigens, CD14: Glycolipid-anchored membrane glycoproteins expressed on cells of the myelomonocyte lineage including monocytes, macrophages, and some granulocytes. They function as receptors for the complex of lipopolysaccharide (LPS) and LPS-binding protein.Antigens, CD2: Glycoprotein members of the immunoglobulin superfamily which participate in T-cell adhesion and activation. They are expressed on most peripheral T-lymphocytes, natural killer cells, and thymocytes, and function as co-receptors or accessory molecules in the T-cell receptor complex.CD4-CD8 Ratio: Ratio of T-LYMPHOCYTES that express the CD4 ANTIGEN to those that express the CD8 ANTIGEN. This value is commonly assessed in the diagnosis and staging of diseases affecting the IMMUNE SYSTEM including HIV INFECTIONS.Antigens, CD5: Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)Antigens, Differentiation: Antigens expressed primarily on the membranes of living cells during sequential stages of maturation and differentiation. As immunologic markers they have high organ and tissue specificity and are useful as probes in studies of normal cell development as well as neoplastic transformation.CD4-Positive T-Lymphocytes: A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.Antigens, CD1: Glycoproteins expressed on cortical thymocytes and on some dendritic cells and B-cells. Their structure is similar to that of MHC Class I and their function has been postulated as similar also. CD1 antigens are highly specific markers for human LANGERHANS CELLS.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Antigens, CD56: The 140 kDa isoform of NCAM (neural cell adhesion molecule) containing a transmembrane domain and short cytoplasmic tail. It is expressed by all lymphocytes mediating non-MHC restricted cytotoxicity and is present on some neural tissues and tumors.Antigens, Differentiation, T-Lymphocyte: Antigens expressed on the cell membrane of T-lymphocytes during differentiation, activation, and normal and neoplastic transformation. Their phenotypic characterization is important in differential diagnosis and studies of thymic ontogeny and T-cell function.ADP-ribosyl Cyclase: A membrane-bound or cytosolic enzyme that catalyzes the synthesis of CYCLIC ADP-RIBOSE (cADPR) from nicotinamide adenine dinucleotide (NAD). This enzyme generally catalyzes the hydrolysis of cADPR to ADP-RIBOSE, as well, and sometimes the synthesis of cyclic ADP-ribose 2' phosphate (2'-P-cADPR) from NADP.Antigens, Differentiation, Myelomonocytic: Surface antigens expressed on myeloid cells of the granulocyte-monocyte-histiocyte series during differentiation. Analysis of their reactivity in normal and malignant myelomonocytic cells is useful in identifying and classifying human leukemias and lymphomas.Antigens, CD80: A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CTLA-4 ANTIGEN with high specificity and to CD28 ANTIGEN with low specificity. The interaction of CD80 with CD28 ANTIGEN provides a costimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.Antigens, CD53: Tetraspanin proteins found at high levels in cells of the lymphoid-myeloid lineage. CD53 antigens may be involved regulating the differentiation of T-LYMPHOCYTES and the activation of B-LYMPHOCYTES.Antigens, CD24: A cell adhesion protein that was originally identified as a heat stable antigen in mice. It is involved in METASTASIS and is highly expressed in many NEOPLASMS.Antigens, CD13: Zinc-binding metalloproteases that are members of the type II integral membrane metalloproteases. They are expressed by GRANULOCYTES; MONOCYTES; and their precursors as well as by various non-hematopoietic cells. They release an N-terminal amino acid from a peptide, amide or arylamide.Antigens, Protozoan: Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.T-Lymphocytes: Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.Antigens, CD86: A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CD28 ANTIGEN with high specificity and to CTLA-4 ANTIGEN with low specificity. The interaction of CD86 with CD28 ANTIGEN provides a stimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.Flow Cytometry: Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.B-Lymphocytes: Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.Antigens, Polyomavirus Transforming: Polyomavirus antigens which cause infection and cellular transformation. The large T antigen is necessary for the initiation of viral DNA synthesis, repression of transcription of the early region and is responsible in conjunction with the middle T antigen for the transformation of primary cells. Small T antigen is necessary for the completion of the productive infection cycle.Antigens, CD95: A tumor necrosis factor receptor subtype found in a variety of tissues and on activated LYMPHOCYTES. It has specificity for FAS LIGAND and plays a role in regulation of peripheral immune responses and APOPTOSIS. Multiple isoforms of the protein exist due to multiple ALTERNATIVE SPLICING. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.HLA Antigens: Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.Antigens, Differentiation, B-Lymphocyte: Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumors of B-cell origin.Antigens, CD45: High-molecular weight glycoproteins uniquely expressed on the surface of LEUKOCYTES and their hemopoietic progenitors. They contain a cytoplasmic protein tyrosine phosphatase activity which plays a role in intracellular signaling from the CELL SURFACE RECEPTORS. The CD45 antigens occur as multiple isoforms that result from alternative mRNA splicing and differential usage of three exons.Immunophenotyping: Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.NAD+ NucleosidaseAntigens, Fungal: Substances of fungal origin that have antigenic activity.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.H-2 Antigens: The major group of transplantation antigens in the mouse.Sialic Acid Binding Ig-like Lectin 3: A 67-kDa sialic acid binding lectin that is specific for MYELOID CELLS and MONOCYTE-MACROPHAGE PRECURSOR CELLS. This protein is the smallest siglec subtype and contains a single immunoglobulin C2-set domain. It may play a role in intracellular signaling via its interaction with SHP-1 PROTEIN-TYROSINE PHOSPHATASE and SHP-2 PROTEIN-TYROSINE PHOSPHATASE.Antigens, Helminth: Any part or derivative of a helminth that elicits an immune reaction. The most commonly seen helminth antigens are those of the schistosomes.Receptors, Antigen, T-Cell: Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (ANTIGENS, CD3). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.Antigens, CD18: Cell-surface glycoprotein beta-chains that are non-covalently linked to specific alpha-chains of the CD11 family of leukocyte-adhesion molecules (RECEPTORS, LEUKOCYTE-ADHESION). A defect in the gene encoding CD18 causes LEUKOCYTE-ADHESION DEFICIENCY SYNDROME.Lymphocyte Activation: Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.Antigens, CD30: A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. They are found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.Membrane Glycoproteins: Glycoproteins found on the membrane or surface of cells.CD8-Positive T-Lymphocytes: A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.Epitopes: Sites on an antigen that interact with specific antibodies.Antigens, CD9: A subtype of tetraspanin proteins that play a role in cell adhesion, cell motility, and tumor metastasis. CD9 antigens take part in the process of platelet activation and aggregation, the formation of paranodal junctions in neuronal tissue, and the fusion of sperm with egg.Carcinoembryonic Antigen: A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.HLA-DR Antigens: A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS.Antigens, CD15: A trisaccharide antigen expressed on glycolipids and many cell-surface glycoproteins. In the blood the antigen is found on the surface of NEUTROPHILS; EOSINOPHILS; and MONOCYTES. In addition, CD15 antigen is a stage-specific embryonic antigen.Antigens, Viral, Tumor: Those proteins recognized by antibodies from serum of animals bearing tumors induced by viruses; these proteins are presumably coded for by the nucleic acids of the same viruses that caused the neoplastic transformation.Cell Line: Established cell cultures that have the potential to propagate indefinitely.Antigens, CD43: A sialic acid-rich protein and an integral cell membrane mucin. It plays an important role in activation of T-LYMPHOCYTES.Antigens, CD36: Leukocyte differentiation antigens and major platelet membrane glycoproteins present on MONOCYTES; ENDOTHELIAL CELLS; PLATELETS; and mammary EPITHELIAL CELLS. They play major roles in CELL ADHESION; SIGNAL TRANSDUCTION; and regulation of angiogenesis. CD36 is a receptor for THROMBOSPONDINS and can act as a scavenger receptor that recognizes and transports oxidized LIPOPROTEINS and FATTY ACIDS.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Antigens, CD11: A group of three different alpha chains (CD11a, CD11b, CD11c) that are associated with an invariant CD18 beta chain (ANTIGENS, CD18). The three resulting leukocyte-adhesion molecules (RECEPTORS, LEUKOCYTE ADHESION) are LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MACROPHAGE-1 ANTIGEN; and ANTIGEN, P150,95.Histocompatibility Antigens Class II: Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen.Histocompatibility Antigens: A group of antigens that includes both the major and minor histocompatibility antigens. The former are genetically determined by the major histocompatibility complex. They determine tissue type for transplantation and cause allograft rejections. The latter are systems of allelic alloantigens that can cause weak transplant rejection.Antigens, CD59: Small glycoproteins found on both hematopoietic and non-hematopoietic cells. CD59 restricts the cytolytic activity of homologous complement by binding to C8 and C9 and blocking the assembly of the membrane attack complex. (From Barclay et al., The Leukocyte Antigen FactsBook, 1993, p234)Receptors, Antigen, B-Cell: IMMUNOGLOBULINS on the surface of B-LYMPHOCYTES. Their MESSENGER RNA contains an EXON with a membrane spanning sequence, producing immunoglobulins in the form of type I transmembrane proteins as opposed to secreted immunoglobulins (ANTIBODIES) which do not contain the membrane spanning segment.Proliferating Cell Nuclear Antigen: Nuclear antigen with a role in DNA synthesis, DNA repair, and cell cycle progression. PCNA is required for the coordinated synthesis of both leading and lagging strands at the replication fork during DNA replication. PCNA expression correlates with the proliferation activity of several malignant and non-malignant cell types.Antigens, CD57: Oligosaccharide antigenic determinants found principally on NK cells and T-cells. Their role in the immune response is poorly understood.Antigens, CD70: A transmembrane protein belonging to the tumor necrosis factor superfamily that specifically binds to CD27 ANTIGEN. It is found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; and DENDRITIC CELLS where it plays a role in stimulating the proliferation of CD4-POSITIVE T-LYMPHOCYTES and CD8-POSITIVE T-LYMPHOCYTES.Antigens, CD46: A ubiquitously expressed complement receptor that binds COMPLEMENT C3B and COMPLEMENT C4B and serves as a cofactor for their inactivation. CD46 also interacts with a wide variety of pathogens and mediates immune response.Lectins, C-Type: A class of animal lectins that bind to carbohydrate in a calcium-dependent manner. They share a common carbohydrate-binding domain that is structurally distinct from other classes of lectins.Antigens, CD58: Glycoproteins with a wide distribution on hematopoietic and non-hematopoietic cells and strongly expressed on macrophages. CD58 mediates cell adhesion by binding to CD2; (ANTIGENS, CD2); and this enhances antigen-specific T-cell activation.Antigens, CD4: 55-kDa antigens found on HELPER-INDUCER T-LYMPHOCYTES and on a variety of other immune cell types. CD4 antigens are members of the immunoglobulin supergene family and are implicated as associative recognition elements in MAJOR HISTOCOMPATIBILITY COMPLEX class II-restricted immune responses. On T-lymphocytes they define the helper/inducer subset. CD4 antigens also serve as INTERLEUKIN-15 receptors and bind to the HIV receptors, binding directly to the HIV ENVELOPE PROTEIN GP120.Antigens, CD47: A ubiquitously expressed membrane glycoprotein. It interacts with a variety of INTEGRINS and mediates responses to EXTRACELLULAR MATRIX PROTEINS.Antigens, CD11b: A CD antigen that contains a conserved I domain which is involved in ligand binding. When combined with CD18 the two subunits form MACROPHAGE-1 ANTIGEN.Base Sequence: The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.Prostate-Specific Antigen: A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.Antigens, CD11c: An integrin alpha subunit of approximately 150-kDa molecular weight. It is expressed at high levels on monocytes and combines with CD18 ANTIGEN to form the cell surface receptor INTEGRIN ALPHAXBETA2. The subunit contains a conserved I-domain which is characteristic of several of alpha integrins.O Antigens: The lipopolysaccharide-protein somatic antigens, usually from gram-negative bacteria, important in the serological classification of enteric bacilli. The O-specific chains determine the specificity of the O antigens of a given serotype. O antigens are the immunodominant part of the lipopolysaccharide molecule in the intact bacterial cell. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)HLA-A2 Antigen: A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*02 allele family.Enzyme-Linked Immunosorbent Assay: An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Hematopoietic Stem Cells: Progenitor cells from which all blood cells derive.CD4 Lymphocyte Count: The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer.Immunoglobulin G: The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.Cell SeparationAntigens, Tumor-Associated, Carbohydrate: Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies.Antigens, CD55: GPI-linked membrane proteins broadly distributed among hematopoietic and non-hematopoietic cells. CD55 prevents the assembly of C3 CONVERTASE or accelerates the disassembly of preformed convertase, thus blocking the formation of the membrane attack complex.Antigens, CD31: Cell adhesion molecules present on virtually all monocytes, platelets, and granulocytes. CD31 is highly expressed on endothelial cells and concentrated at the junctions between them.Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Histocompatibility Antigens Class I: Membrane glycoproteins consisting of an alpha subunit and a BETA 2-MICROGLOBULIN beta subunit. In humans, highly polymorphic genes on CHROMOSOME 6 encode the alpha subunits of class I antigens and play an important role in determining the serological specificity of the surface antigen. Class I antigens are found on most nucleated cells and are generally detected by their reactivity with alloantisera. These antigens are recognized during GRAFT REJECTION and restrict cell-mediated lysis of virus-infected cells.Antigens, CD81: Tetraspanin proteins that are involved in a variety of cellular functions including BASEMENT MEMBRANE assembly, and in the formation of a molecular complexes on the surface of LYMPHOCYTES.Cells, Cultured: Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.Antigens, CD137: A member of the tumor necrosis factor receptor superfamily that is specific for 4-1BB LIGAND. It is found in a variety of immune cell types including activated T-LYMPHOCYTES; NATURAL KILLER CELLS; and DENDRITIC CELLS. Activation of the receptor on T-LYMPHOCYTES plays a role in their expansion, production of cytokines and survival. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.Cell Differentiation: Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.Recombinant Proteins: Proteins prepared by recombinant DNA technology.Lymphocytes: White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.Mice, Inbred BALB CMonocytes: Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles.HLA-A Antigens: Polymorphic class I human histocompatibility (HLA) surface antigens present on almost all nucleated cells. At least 20 antigens have been identified which are encoded by the A locus of multiple alleles on chromosome 6. They serve as targets for T-cell cytolytic responses and are involved with acceptance or rejection of tissue/organ grafts.Cross Reactions: Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.Dendritic Cells: Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).Receptors, Interleukin-2: Receptors present on activated T-LYMPHOCYTES and B-LYMPHOCYTES that are specific for INTERLEUKIN-2 and play an important role in LYMPHOCYTE ACTIVATION. They are heterotrimeric proteins consisting of the INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT, the INTERLEUKIN-2 RECEPTOR BETA SUBUNIT, and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN.Blood Group Antigens: Sets of cell surface antigens located on BLOOD CELLS. They are usually membrane GLYCOPROTEINS or GLYCOLIPIDS that are antigenically distinguished by their carbohydrate moieties.Hepatitis B Surface Antigens: Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.Antigens, CD63: Ubiquitously-expressed tetraspanin proteins that are found in late ENDOSOMES and LYSOSOMES and have been implicated in intracellular transport of proteins.Transfection: The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.Antibody Specificity: The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.Antigens, CD151: Tetraspanin proteins found associated with LAMININ-binding INTEGRINS. The CD151 antigens may play a role in the regulation of CELL MOTILITY.Antigens, CD79: A component of the B-cell antigen receptor that is involved in B-cell antigen receptor heavy chain transport to the PLASMA MEMBRANE. It is expressed almost exclusively in B-LYMPHOCYTES and serves as a useful marker for B-cell NEOPLASMS.Spleen: An encapsulated lymphatic organ through which venous blood filters.Fluorescent Antibody Technique: Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.HLA-D Antigens: Human immune-response or Class II antigens found mainly, but not exclusively, on B-lymphocytes and produced from genes of the HLA-D locus. They are extremely polymorphic families of glycopeptides, each consisting of two chains, alpha and beta. This group of antigens includes the -DR, -DQ and -DP designations, of which HLA-DR is most studied; some of these glycoproteins are associated with certain diseases, possibly of immune etiology.CD30 Ligand: A membrane-bound tumor necrosis family member found primarily on activated T-LYMPHOCYTES that binds specifically to CD30 ANTIGEN. It may play a role in INFLAMMATION and immune regulation.Phenotype: The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.N-Glycosyl Hydrolases: A class of enzymes involved in the hydrolysis of the N-glycosidic bond of nitrogen-linked sugars.Burkitt Lymphoma: A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.Receptors, Antigen: Molecules on the surface of B- and T-lymphocytes that recognize and combine with specific antigens.Immunization: Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).Antibody Formation: The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.Antigens, CD11a: An alpha-integrin subunit found on lymphocytes, granulocytes, macrophages and monocytes. It combines with the integrin beta2 subunit (CD18 ANTIGEN) to form LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Hepatitis B Antigens: Antigens of the virion of the HEPATITIS B VIRUS or the Dane particle, its surface (HEPATITIS B SURFACE ANTIGENS), core (HEPATITIS B CORE ANTIGENS), and other associated antigens, including the HEPATITIS B E ANTIGENS.Bone Marrow: The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.Antigen-Antibody Reactions: The processes triggered by interactions of ANTIBODIES with their ANTIGENS.Immune Sera: Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen.Macrophages: The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.)Mice, SCID: Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.T-Lymphocytes, Cytotoxic: Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.Recombinant Fusion Proteins: Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.Cell Division: The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.Antigen-Presenting Cells: A heterogeneous group of immunocompetent cells that mediate the cellular immune response by processing and presenting antigens to the T-cells. Traditional antigen-presenting cells include MACROPHAGES; DENDRITIC CELLS; LANGERHANS CELLS; and B-LYMPHOCYTES. FOLLICULAR DENDRITIC CELLS are not traditional antigen-presenting cells, but because they hold antigen on their cell surface in the form of IMMUNE COMPLEXES for B-cell recognition they are considered so by some authors.Herpesvirus 4, Human: The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies.Receptors, Antigen, T-Cell, alpha-beta: T-cell receptors composed of CD3-associated alpha and beta polypeptide chains and expressed primarily in CD4+ or CD8+ T-cells. Unlike immunoglobulins, the alpha-beta T-cell receptors recognize antigens only when presented in association with major histocompatibility (MHC) molecules.Antibodies, Bacterial: Immunoglobulins produced in a response to BACTERIAL ANTIGENS.HLA-B Antigens: Class I human histocompatibility (HLA) surface antigens encoded by more than 30 detectable alleles on locus B of the HLA complex, the most polymorphic of all the HLA specificities. Several of these antigens (e.g., HLA-B27, -B7, -B8) are strongly associated with predisposition to rheumatoid and other autoimmune disorders. Like other class I HLA determinants, they are involved in the cellular immune reactivity of cytolytic T lymphocytes.Immunologic Memory: The altered state of immunologic responsiveness resulting from initial contact with antigen, which enables the individual to produce antibodies more rapidly and in greater quantity in response to secondary antigenic stimulus.Bone Marrow Cells: Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.Cytotoxicity, Immunologic: The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.Mice, Transgenic: Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.MART-1 Antigen: A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.Antigens, CD147: A widely distributed cell surface transmembrane glycoprotein that stimulates the synthesis of MATRIX METALLOPROTEINASES. It is found at high levels on the surface of malignant NEOPLASMS and may play a role as a mediator of malignant cell behavior.Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.Mice, Inbred C57BLOvalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.HIV Antigens: Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens.CTLA-4 Antigen: An inhibitory T CELL receptor that is closely related to CD28 ANTIGEN. It has specificity for CD80 ANTIGEN and CD86 ANTIGEN and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing PERIPHERAL TOLERANCE.HL-60 Cells: A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8)Antigens, CD82: A widely expressed transmembrane glycoprotein that functions as a METASTASIS suppressor protein. It is underexpressed in a variety of human NEOPLASMS.Immunoenzyme Techniques: Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.Antibodies: Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).Gene Expression: The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.Antigens, Thy-1: A group of differentiation surface antigens, among the first to be discovered on thymocytes and T-lymphocytes. Originally identified in the mouse, they are also found in other species including humans, and are expressed on brain neurons and other cells.Cytokines: Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.Immune Tolerance: The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.Immunity, Cellular: Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.Thymus Gland: A single, unpaired primary lymphoid organ situated in the MEDIASTINUM, extending superiorly into the neck to the lower edge of the THYROID GLAND and inferiorly to the fourth costal cartilage. It is necessary for normal development of immunologic function early in life. By puberty, it begins to involute and much of the tissue is replaced by fat.Autoantigens: Endogenous tissue constituents that have the ability to interact with AUTOANTIBODIES and cause an immune response.Clone Cells: A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)Epstein-Barr Virus Nuclear Antigens: Nuclear antigens encoded by VIRAL GENES found in HUMAN HERPESVIRUS 4. At least six nuclear antigens have been identified.Interleukin-2: A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.Immunoglobulin M: A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.Cell Line, Tumor: A cell line derived from cultured tumor cells.Biological Markers: Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.H-Y Antigen: A sex-specific cell surface antigen produced by the sex-determining gene of the Y chromosome in mammals. It causes syngeneic grafts from males to females to be rejected and interacts with somatic elements of the embryologic undifferentiated gonad to produce testicular organogenesis.Antigens, CD146: A cell adhesion molecule of the immunoglobulin superfamily that is expressed in ENDOTHELIAL CELLS and is involved in INTERCELLULAR JUNCTIONS.Antigens, Heterophile: Antigens stimulating the formation of, or combining with heterophile antibodies. They are cross-reacting antigens found in phylogenetically unrelated species.T-Lymphocytes, Regulatory: CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells.Antibodies, Monoclonal, Murine-Derived: Antibodies obtained from a single clone of cells grown in mice or rats.Epitopes, T-Lymphocyte: Antigenic determinants recognized and bound by the T-cell receptor. Epitopes recognized by the T-cell receptor are often located in the inner, unexposed side of the antigen, and become accessible to the T-cell receptors after proteolytic processing of the antigen.Interferon-gamma: The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.Antigens, CD98: A heterodimeric protein that is a cell surface antigen associated with lymphocyte activation. The initial characterization of this protein revealed one identifiable heavy chain (ANTIGENS, CD98 HEAVY CHAIN) and an indeterminate smaller light chain. It is now known that a variety of light chain subunits (ANTIGENS, CD98 LIGHT CHAINS) can dimerize with the heavy chain. Depending upon its light chain composition a diverse array of functions can be found for this protein. Functions include: type L amino acid transport, type y+L amino acid transport and regulation of cellular fusion.Hepatitis B Core Antigens: The hepatitis B antigen within the core of the Dane particle, the infectious hepatitis virion.Peptides: Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.Antigen-Antibody Complex: The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.Lymph Nodes: They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.Molecular Weight: The sum of the weight of all the atoms in a molecule.Immunodiffusion: Technique involving the diffusion of antigen or antibody through a semisolid medium, usually agar or agarose gel, with the result being a precipitin reaction.HLA-DQ Antigens: A group of the D-related HLA antigens found to differ from the DR antigens in genetic locus and therefore inheritance. These antigens are polymorphic glycoproteins comprising alpha and beta chains and are found on lymphoid and other cells, often associated with certain diseases.Antibodies, Viral: Immunoglobulins produced in response to VIRAL ANTIGENS.Signal Transduction: The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.Mice, Inbred Strains: Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.Forssman Antigen: A glycolipid, cross-species antigen that induces production of antisheep hemolysin. It is present on the tissue cells of many species but absent in humans. It is found in many infectious agents.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Rabbits: The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.Antigens, CD274: An inhibitory B7 antigen that has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 PROTEIN. CD274 antigen provides negative signals that control and inhibit T-cell responses and is found at higher than normal levels on tumor cells, suggesting its potential role in TUMOR IMMUNE EVASION.Complement Fixation Tests: Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualized by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (hemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1.Simian virus 40: A species of POLYOMAVIRUS originally isolated from Rhesus monkey kidney tissue. It produces malignancy in human and newborn hamster kidney cell cultures.Glycoproteins: Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.Adjuvants, Immunologic: Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.Isoantigens: Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by species members who lack it, an immune response is induced. Typical isoantigens are the BLOOD GROUP ANTIGENS.Hybridomas: Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell.gp100 Melanoma Antigen: A melanosome-associated protein that plays a role in the maturation of the MELANOSOME.Major Histocompatibility Complex: The genetic region which contains the loci of genes which determine the structure of the serologically defined (SD) and lymphocyte-defined (LD) TRANSPLANTATION ANTIGENS, genes which control the structure of the IMMUNE RESPONSE-ASSOCIATED ANTIGENS, HUMAN; the IMMUNE RESPONSE GENES which control the ability of an animal to respond immunologically to antigenic stimuli, and genes which determine the structure and/or level of the first four components of complement.Killer Cells, Natural: Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.Immunoelectrophoresis: A technique that combines protein electrophoresis and double immunodiffusion. In this procedure proteins are first separated by gel electrophoresis (usually agarose), then made visible by immunodiffusion of specific antibodies. A distinct elliptical precipitin arc results for each protein detectable by the antisera.

Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. (1/4274)

Angiosarcomas apparently derive from blood vessel endothelial cells; however, occasionally their histological features suggest mixed origin from blood and lymphatic endothelia. In the absence of specific positive markers for lymphatic endothelia the precise distinction between these components has not been possible. Here we provide evidence by light and electron microscopic immunohistochemistry that podoplanin, a approximately 38-kd membrane glycoprotein of podocytes, is specifically expressed in the endothelium of lymphatic capillaries, but not in the blood vasculature. In normal skin and kidney, podoplanin colocalized with vascular endothelial growth factor receptor-3, the only other lymphatic marker presently available. Complementary immunostaining of blood vessels was obtained with established endothelial markers (CD31, CD34, factor VIII-related antigen, and Ulex europaeus I lectin) as well as podocalyxin, another podocytic protein that is also localized in endothelia of blood vessels. Podoplanin specifically immunolabeled endothelia of benign tumorous lesions of undisputed lymphatic origin (lymphangiomas, hygromas) and was detected there as a 38-kd protein by immunoblotting. As paradigms of malignant vascular tumors, poorly differentiated (G3) common angiosarcomas (n = 8), epitheloid angiosarcomas (n = 3), and intestinal Kaposi's sarcomas (n = 5) were examined for their podoplanin content in relation to conventional endothelial markers. The relative number of tumor cells expressing podoplanin was estimated and, although the number of cases in this preliminary study was limited to 16, an apparent spectrum of podoplanin expression emerged that can be divided into a low-expression group in which 0-10% of tumor cells contained podoplanin, a moderate-expression group with 30-60% and a high-expression group with 70-100%. Ten of eleven angiosarcomas and all Kaposi's sarcomas showed mixed expression of both lymphatic and blood vascular endothelial phenotypes. By double labeling, most podoplanin-positive tumor cells coexpressed endothelial markers of blood vessels, whereas few tumor cells were positive for individual markers only. From these results we conclude that (1) podoplanin is a selective marker of lymphatic endothelium; (2) G3 angiosarcomas display a quantitative spectrum of podoplanin-expressing tumor cells; (3) in most angiosarcomas, a varying subset of tumor cells coexpresses podoplanin and endothelial markers of blood vessels; and (4) all endothelial cells of Kaposi's sarcomas expressed the lymphatic marker podoplanin.  (+info)

Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. (2/4274)

Angiogenesis is essential for tumor growth and metastasis. There are conflicting reports as to whether microvessel density (IMD) in breast cancers is associated with prognosis. This could be due to the use of different antibodies to endothelial cell markers, variation in tissue pretreatment protocols, and nonstandardized counting methods. We have assessed the IMD in 106 breast carcinomas using a pan-endothelial marker, CD34, and a recently described mAb to CD105, which preferentially reacts with endothelial cell in angiogenic tissues. IMD values (separated as above or below median) for CD105 expression showed a statistically significant correlation with overall (P = 0.0029) and disease-free survival (P = 0.0362). In contrast, blood vessel counts using a panendothelial marker CD34 did not correlate with overall or disease-free survival (P = 0.2912 and P = 03153, respectively). When IMD values were subdivided into quartiles and assessed for their prognostic values, there was a statistically significant difference in the overall survival across CD105, but not CD34, values (P = 0.0017 and P = 0.7997, respectively) and also disease-free survival (P = 0.0431 and P = 0.5066, respectively). Further analysis of IMD values demonstrated that there were no deaths in the lowest quartile for CD105 and it differed from the other three quartiles. However, examination of clinical details of patients in the lowest quartile failed to reveal clustering of patients known to be associated with low-risk factors. Multivariate analysis confirmed that IMD values using CD105 were an independent prognostic factor. These results suggest that the ability to quantitatively distinguish between tumor neovascularization and preexisting vessels may be important in the assessment of tumor angiogenesis, but requires confirmation in a greater number of patients with a longer follow-up.  (+info)

Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF. (3/4274)

We have evaluated the immunophenotype, functional activity and clonogenic potential of CD34+ cells from peripheral blood (PB) of normal donors before and after 4 and 6 days of G-CSF administration. The percentage and absolute number of CD34+ cells significantly increased at days 4 and 6 of G-CSF administration, compared to the steady-state level (P < 0.0001). Two-colour fluorescence analysis showed, at days 4 and 6, a lower proportion of CD34+/c-kit+ compared to the steady-state level (P < 0.0001), but a similar expression of CD13, CD33, CD38, HLA-DR and Thy-1 antigens on CD34+ cells. The expression of adhesion molecules on CD34+ cells revealed a significant reduction of CD11a (P = 0.009), CD18, CD49d and CD62L (P < 0.0001) at days 4 and 6, compared to the baseline level. Three-colour staining showed a reduction of the more immature compartment (34+/DR-/13-) and an increase of the more differentiated compartment (34+/DR+/13+). Downregulation of VLA-4 during mobilisation was seen almost exclusively on more committed cells (34+/13+); downregulation of CD62L, on the contrary, was observed on both early progenitors (34+/13-) and more committed cells (34+/13+). The expression of 34+/VLA-4+ decreased on both c-kit+ and c-kit- cells, while the expression of 34+/62L+ decreased on the c-kit+ cells only. In vivo administration of G-CSF reduced the adherence capacity of CD34+ cells to normal BM stroma; in vitro incubation with SCF or IL-3 enhanced the expression of CD49d on CD34+ cells, while GM-CSF reduced the expression of CD62L. SCF was the only cytokine able to induce a significant increase of CD34+ cell adherence to preformed stroma. Pre-incubation with the blocking beta2 integrin monoclonal antibody caused a reduction of CD34+ cell adherence. In conclusion, the decrease of CD49d expression on mobilized CD34+ cells correlates with a poor adhesion to BM stroma; CD34+ cells incubated in vitro with SCF showed, conversely, a higher expression of CD49d and a greater adherence capacity on normal preformed stroma.  (+info)

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. (4/4274)

We analysed 57 patients with non-myeloid malignancies who received a non-purged autologous PBSCT. All had similar mobilisation and conditioning regimens. A high prior chemotherapy score and the number of chemotherapy lines used (P = 0.015 and P = 0.01, respectively) were adverse predictors of CD34 cell yields. Lower CD34 values (P = 0.002) were seen in patients treated with potent stem cell toxins (BCNU, melphalan, CCNU and mustine), designated toxicity factor 4 agents (TF4). All patients infused with grafts containing CD34 cell doses between 1.0 and 2.0 x 10(6)/kg (range 1.25-1.90) engrafted by day 51. The only variable associated with slow platelet recovery was exposure to TF4 (P = 0.007). The majority of patients with CD34 >1.0 x 10(6)/kg achieved rapid and sustained engraftment and the only predictive factor of delayed recovery is prior exposure to stem cell toxins. Potential PBSCT candidates should if possible avoid first line and salvage chemotherapy containing TF4 drugs. We therefore advocate a minimum CD34 threshold of >1.0 x 10(6)/kg in patients without extensive prior chemoradiotherapy, and > or = 2.0 x 10(6)/kg in all other patients.  (+info)

Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. (5/4274)

High-dose chemotherapy followed by autologous transplantation has been shown to improve response rates and survival in multiple myeloma and other malignancies. However, autografts frequently contain detectable tumor cells. Enrichment for stem cells using anti-CD34 antibodies has been shown to reduce autograft tumor contamination in phase I/II studies. To more definitively assess the safety and efficacy of CD34 selection, a phase III study was completed in 131 multiple myeloma patients randomized to receive an autologous transplant with either CD34-selected or unselected peripheral blood progenitor cells after myeloablative therapy. Tumor contamination in the autografts was assessed by a quantitative polymerase chain reaction detection assay using patient-specific, complementarity-determining region (CDR) Ig gene primers before and after CD34 selection. A median 3.1 log reduction in contaminating tumor cells was achieved in the CD34 selected product using the CEPRATE SC System (CellPro, Inc, Bothell, WA). Successful neutrophil engraftment was achieved in all patients by day 15 and no significant between-arm difference for time to platelet engraftment occurred in patients who received an infused dose of at least 2.0 x 10(6) CD34(+) cells/kg. In conclusion, this phase III trial demonstrates that CD34-selection of peripheral blood progenitor cells significantly reduces tumor cell contamination yet provides safe and rapid hematologic recovery for patients receiving myeloablative therapy.  (+info)

Transduction of primitive human marrow and cord blood-derived hematopoietic progenitor cells with adeno-associated virus vectors. (6/4274)

We evaluated the capacity of adeno-associated virus (AAV) vectors to transduce primitive human myeloid progenitor cells derived from marrow and cord blood in long-term cultures and long-term culture-initiating cell (LTC-IC) assays. Single-colony analyses showed that AAV vectors transduced CD34(+) and CD34(+)38(-) clonogenic cells in long-term culture. Gene transfer was readily observed in LTC-ICs derived from 5-, 8-, and 10-week cultures. Recombinant AAV (rAAV) transduction was observed in every donor analyzed, although a wide range of gene transfer frequencies (5% to 100%) was noted. AAV transduction of LTC-ICs was stable, with week-8 and -10 LTC-ICs showing comparable or better transduction relative to week-5 LTC-ICs. Fluorescence in situ hybridization (FISH) analyses performed to determine the fate of AAV vectors in transduced cells showed that 9% to 28% of CD34(+) and CD34(+)38(-) cells showed stable vector integration as evidenced by chromosome-associated signals in metaphase spreads. Comparisons of interphase and metaphase FISH suggested that a fraction of cells also contained episomal vector at early time points after transduction. Despite the apparent loss of the episomal forms with continued culture, the number of metaphases containing integrated vector genomes remained stable long term. Transgene transcription and placental alkaline phosphatase (PLAP) expression was observed in CD34(+), CD34(+)38(-) LTC-ICs in the absence of selective pressure. These results suggest that primitive myeloid progenitors are amenable to genetic modification with AAV vectors.  (+info)

Cyclin A1 expression in leukemia and normal hematopoietic cells. (7/4274)

Human cyclin A1 is a newly cloned, tissue-specific cyclin that is prominently expressed in normal testis. In this study, we showed that cyclin A1 was highly expressed in a subset of leukemia samples from patients. The highest frequency of cyclin A1 overexpression was observed in acute myelocytic leukemias, especially those that were at the promyelocyte (M3) and myeloblast (M2) stages of development. Cyclin A1 expression was also detected in normal CD34(+) progenitor cells. The expression of cyclin A1 increased when these cells were stimulated to undergo myeloid differentiation in vitro. Taken together, our observations suggest that cyclin A1 may have a role in hematopoiesis. High levels of cyclin A1 expression are especially associated with certain leukemias blocked at the myeloblast and promyelocyte stages of differentiation.  (+info)

Detection of small numbers of immature cells in the blood of healthy subjects. (8/4274)

AIMS: To determine the frequency of immature haemopoietic cells in the peripheral blood of healthy persons. METHODS: Cytocentrifuge preparations were made using mononuclear leucocytes separated by a Ficoll-Hypaque density gradient. The slides were stained by May-Grunwald-Giemsa. The combination with immunoperoxidase technique allowed immunotyping of uncommon blood cells. RESULTS: Blast cells expressing the progenitor cell marker CD34 represented 0.11 (0.06) per cent (mean (SD)) of the total mononuclear leucocyte count; these were the haemopoietic progenitor cells in the peripheral blood. Dark blue cells expressing CD38, CD45, HLA-DR, CD4, CD11a, CD29, CD49d, CD50, and CD54 represented 0.30 (0.21) per cent of the mononuclear leucocytes; most of these cells did not express T, B, NK, myelomonocytic, progenitor cell, proliferation, activation, blood dendritic cell, or follicular dendritic cell markers. These were dendritic cell precursors in the peripheral blood. Very small numbers of cells expressing CD83 were found. Blast-like cells expressing CD45, HLA-DR, CD11a, and CD50 represented 0.15 (0.10) per cent of the mononuclear leucocytes; morphology and immunotyping supported the conclusion that these cells were poorly differentiated monocytes. CONCLUSIONS: Morphological investigation of mononuclear leucocytes in peripheral blood of healthy persons can be used to detect small numbers of blasts, dark blue cells, and blast-like cells. The immunoperoxidase technique can then be used for immunotyping of these cells. This simple method may be helpful in diagnosing haematological disorders.  (+info)

*SUPT20H

"Novel transcription factors in human CD34 antigen-positive hematopoietic cells". Blood. 100 (1): 107-19. doi:10.1182/blood. ...

*CD34

Hematopoietic progenitor cell antigen CD34 also known as CD34 antigen is a protein that in humans is encoded by the CD34 gene. ... Antigens, CD34 at the US National Library of Medicine Medical Subject Headings (MeSH) Mouse CD Antigen Chart Human CD Antigen ... CD34 CD34 molecule". Simmons DL, Satterthwaite AB, Tenen DG, Seed B (Jan 1992). "Molecular cloning of a cDNA encoding CD34, a ... "Structural and partial amino acid sequence analysis of the human hemopoietic progenitor cell antigen CD34". Leukemia. 2 (12): ...

*CD68

... the hematopoietic mucin-like family of molecules that includes leukosialin/CD43 and stem cell antigen CD34; the lysosomal/ ... "MACROPHAGE ANTIGEN CD68; CD68". omim.org. Retrieved 16 September 2017. Leong, Anthony S-Y; Cooper, Kumarason; Leong, F Joel W-M ... Other names or aliases for this gene in humans and other animals include: CD68 Molecule, CD68 Antigen, GP110, Macrosialin, ... Damoiseaux, JG; Döpp, EA; Calame, W; Chao, D; MacPherson, GG; Dijkstra, CD (1994). "Rat macrophage lysosomal membrane antigen ...

*Mast cell

... since part of them is positive for the CD34 antigen. The classical mast cell markers include the high-affinity IgE receptor, ... The antigen cross-links the FcεR1 molecules, and Lyn tyrosine kinase phosphorylates the ITAMs in the FcεR1 β and γ chain in the ... This antigen stimulated phosphorylation causes the activation of other proteins in the FcεR1-mediated signaling cascade. An ... The Fc region of immunoglobulin E (IgE) becomes bound to mast cells and basophils and when IgE's paratopes bind to an antigen, ...

*List of MeSH codes (D23)

... antigens, cd30 MeSH D23.050.301.264.035.131 --- antigens, cd31 MeSH D23.050.301.264.035.134 --- antigens, cd34 MeSH D23.050. ... antigens, cd30 MeSH D23.101.100.110.131 --- antigens, cd31 MeSH D23.101.100.110.134 --- antigens, cd34 MeSH D23.101.100.110.136 ... hla-a antigens MeSH D23.050.301.500.450.370.372 --- hla-a1 antigen MeSH D23.050.301.500.450.370.374 --- hla-a2 antigen MeSH ... hla-b antigens MeSH D23.050.301.500.450.380.383 --- hla-b7 antigen MeSH D23.050.301.500.450.380.385 --- hla-b8 antigen MeSH ...

*Epithelioid sarcoma

... s typically express vimentin, cytokeratins, epithelial membrane antigen, and CD34, whereas they are usually ... Adoptive immunotherapy seeks to expand a population of the body's T-cells that will recognize a specific tumor antigen. T-cells ... They can also include the administration of laboratory-produced antibodies specific to tumor antigens to create or boost an ... Vaccines can deliver various tumor-associated factors (tumor antigens) to the immune system, resulting in a natural antibody ...

*Minimally differentiated acute myeloblastic leukemia

The blasts react with antibodies to myeloperoxidase and antibodies to CD13, CD33, and CD34. Human leukocyte antigen (HLA)-DR is ... but immunophenotyping demonstrates myeloid antigens. In acute myeloblastic leukemia (M0), the blasts are agranular and ...

*Sperm-associated antigen 7

"Identification of genes expressed in human CD34(+) hematopoietic stem/progenitor cells by expressed sequence tags and efficient ... Sperm-associated antigen 7 is a protein that in humans is encoded by the SPAG7 gene. GRCh38: Ensembl release 89: ... "Entrez Gene: SPAG7 sperm associated antigen 7". Suzuki Y, Yamashita R, Shirota M, Sakakibara Y, Chiba J, Mizushima-Sugano J, ...

*Cord blood bank

... known as their human leukocyte antigen (HLA) types. Bone marrow transplants require a complete match on six key antigens, which ... CD34), and bacterial and fungal growth. After the collection, the cord blood unit is shipped to the lab and processed, and then ... It will also be examined for nucleated cell count, cell viability, blood group antigen ABO & Rh blood group system, molecule ... and tissue typing to determine Human Leukocyte Antigen type. ...

*Outline of immunology

Antigen Antigenicity Immunogen Superantigen Allergen Hapten Epitope Linear Conformational Mimotope Tumor antigen Antigen- ... SLAMF9 Cadherins Selectins E-selectin L-selectin P-selectin Others Lymphocyte homing receptors CD34 GLYCAM-1 Addressin (MAdCAM- ... T cells Antigen receptor - T cell receptor (TCR) Subunits - [email protected] / [email protected] / [email protected] / [email protected] Co-receptors CD8 (CD8α / CD8β) CD4 ... B cells Antigen receptor - B cell receptor (BCR) Subunits- Immunoglobulin heavy chain / Immunoglobulin light chain Co-receptors ...

*Hematopoietic stem cell

CD34+CD16/32hi Megakaryocyte-erythroid progenitor (MEP): lin−SCA-1−c-kit+CD34−CD16/32low For HSCs, CD150+CD48− was sufficient ... hematopoietic cell surface antigen defined by a monoclonal antibody raised against KG-1a cells". Journal of Immunology. 133 (1 ... For human HSCs use of CD133 was one step ahead as both CD34+ and CD34− HSCs were CD133+. Traditional purification method used ... Also, some of these markers (e.g., Thy1) are not conserved across mouse species, and use of markers like CD34− for HSC ...

*Duffy antigen system

Duffy antigen receptor for chemokines, von Willebrand factor, CD31, CD34, CD105 and CD146". J. Pathol. 206 (3): 260-8. doi: ... Because the Duffy antigen is uncommon in those of Black African descent, the presence of this antigen has been used to detect ... This antigen along with other blood group antigens was used to identify the Basque people as a genetically separate group. Its ... The Duffy antigen is expressed in greater quantities on reticulocytes than on mature erythrocytes. While the Duffy antigen is ...

*Induced stem cells

DC-like antigen-presenting cells obtained from human induced pluripotent stem cells can serve as a source for vaccination ... Red blood cells (RBC)s generated in vitro from mobilized CD34 positive cells have normal survival when transfused into an ... Thus, the ability to generate platelet products ex vivo and platelet products lacking HLA antigens in serum-free media would ... A potentially efficient approach for generating antigen-specific CTLs is to revert mature immune T cells into iPSCs, which ...

*Cancer stem cell

Bonnet and Dick isolated a subpopulation of leukemia cells that expressed surface marker CD34, but not CD38. The authors ... stage-specific embryonic antigen-1), EGFR and CD44. The use of CD133 for identification of brain tumor stem-like cells may be ... Markers most frequently used for CSC isolation include: CD133 (also known as PROM1), CD44, ALDH1A1, CD34, CD24 and EpCAM ( ... The cell surface receptor interleukin-3 receptor-alpha (CD123) is overexpressed on CD34+CD38- leukemic stem cells (LSCs) in ...

*Index of oncology articles

CD34 antigen - CD40-ligand - CEA - CEA assay - cecum - cefalexin - cefepime - cefixime - ceftriaxone - celecoxib - celiac ... antigen - antigen-presenting cell - antigen-presenting cell vaccine - antiglobulin test - antihormone therapy - antimetabolite ... human leukocyte antigen - human lymphocyte antigen - human papillomavirus - human T-cell leukemia virus type 1 - Hürthle cell ... prostate-specific antigen - prostate-specific antigen test - prostatectomy - prostatic acid phosphatase - prostatic ...

*Hemangioblast

These cells are thought to express both CD34 and CD133 These cells are likely derived from the bone marrow, and may even be ... 2009). "Human embryonic stem cells hemangioblast express HLA-antigens". J Transl Med. 7 (1): 27. doi:10.1186/1479-5876-7-27. ... It has been shown that these pre-endothelial/pre-hematopoietic cells in the embryo arise out of a phenotype CD34 population. It ... CD34, Scl, Gata2, Runx1, and Pecam-1. Furthermore, it was shown that depletion of Flk1 in the developing embryo results in ...

*CD90

It is considered a major marker of HSC pluripotency in concordance with CD34. In human HSCs, Thy1 cells are all CD34 positive. ... It was originally named theta (θ) antigen, then Thy-1 (THYmocyte differentiation antigen 1) due to its prior identification in ... The antigen Thy-1 was the first T cell marker to be identified. Thy-1 was discovered by Reif and Allen in 1964 during a search ... Amongst the cells reported to generally express Thy-1 are thymocytes (precursor of T cells in the thymus) & CD34(+) ...

*L-selectin

... need to enter secondary lymph nodes to encounter their antigen. Central memory T-lymphocytes, which have encountered antigen, ... CD34, found on endothelial cells. MadCAM-1, found on endothelial cells of gut-associated lymphoid tissue. PSGL-1, binds with ... Here they reside ready to proliferate upon re-encountering antigen. Effector memory T-lymphocytes do not express L-selectin, as ... 1998). "Identification of podocalyxin-like protein as a high endothelial venule ligand for L-selectin: parallels to CD34". J. ...

*High endothelial venules

T cells become activated by recognising foreign antigens bound to antigen presenting cells (APC), in particular, dendritic ... The rolling mechanism helps the L-selectin molecules on the surface of naive T cells to weakly interact with GlyCAM-1 and CD34 ... Since antigen levels are usually low, contact in blood circulation would be unlikely. Therefore, T cells need a region where ... When an APC, such as a dendritic cell, binds a foreign antigen it becomes activated and moves into the lymph nodes (sites for ...

*Gustav Gaudernack

At the end of the 1980s the three-dimensional structure of human leukocyte antigen (HLA) molecule was defined in parallel to ... He further generated monoclonal antibodies specific for the hematopoietic stem cell marker, CD34. A joint collaboration with ... These data clearly demonstrated vaccine-specific immune responses with a broad specter of T cell response against antigens ... Hospital and Baxter resulted in development of an instrument to isolate hematopoietic stem cells in large scale using anti-CD34 ...

*Cluster of differentiation

White Cell Differentiation Antigens. Oxford University Press. Knapp, W; et al. (1989). Leucocyte Typing IV. Oxford University ... For example, a "CD34+, CD31−" cell is one that expresses CD34, but not CD31. This CD combination typically corresponds to a ... "CD Antigens" (PDF). abcam. 2009. Retrieved 2014-11-22. Passlick B, Flieger D, Ziegler-Heitbrock HW (1989). "Identification and ... In the example of CD4 & CD8, these molecules are critical in antigen recognition. Others (e.g., CD135) act as cell surface ...

*Sialyl-Lewis X

When sialyl-Lewisx is part of an O-glycan and attached to CD34 it can then bind to L-selectin. For the binding to L-selectin to ... Sialyl Lewis X is also one of the most important blood group antigens and is displayed on the terminus of glycolipids that are ... Sialyl Lewis x is an inflammation-associated antigen on liver cells. It becomes over expressed on diseased liver cells and can ... Defective synthesis of the sialyl Lewis X antigen results in immunodeficiency (leukocyte adhesion deficiency type 2). Defective ...

*CD109

2002). "Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing ... 2003). "Antibody W7C5 defines a CD109 epitope expressed on CD34+ and CD34- hematopoietic and mesenchymal stem cell subsets". ... CD109 Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) Human CD109 genome location and CD109 gene ... CD109 is a GPI-linked cell surface antigen expressed by CD34+ acute myeloid leukemia cell lines, T-cell lines, activated T ...

*Thymocyte

The ability of T cells to recognize foreign antigens is mediated by the T cell receptor (TCR), which is a surface protein able ... Still during the double negative stage, CD34 expression stops and CD1 is expressed. Expression of both CD4 and CD8 makes them ... This allows single positive thymocytes to be exposed to a more complex set of self-antigens than is present in the cortex, and ... Cells which do not have a high affinity for self-antigens survive negative selection. At this stage, some cells are also ...

*Stem cell marker

CK19, Cytokeratin 19, K19) Kit L-selectin (CD62L) Lamin A/C Lewis X antigen (Le(X)) LeX Lgr5 Lrp4 MCM2 MCSP Metallothionein (MT ... 1 February 2000). "Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional ... June 2005). "Podocalyxin is a CD34-related marker of murine hematopoietic stem cells and embryonic erythroid cells". Blood. 105 ... May 2006). "Lack of expression of the chondroitin sulphate proteoglycan neuron-glial antigen 2 on candidate stem cell ...

*PODXL

This gene encodes a member of the CD34 sialomucin protein family. The encoded protein was originally identified as an important ... Schopperle WM, Kershaw DB, DeWolf WC (Jan 2003). "Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin". ... parallels to CD34". The Journal of Experimental Medicine. 187 (12): 1965-75. doi:10.1084/jem.187.12.1965. PMC 2212365 . PMID ... "Novel functions of the CD34 family". Journal of Cell Science. 121 (Pt 22): 3683-92. doi:10.1242/jcs.037507. PMID 18987355. ...
TY - JOUR. T1 - Decreased homing of retrovirally transduced human bone marrow CD34 + cells in the NOD/SCID mouse model. AU - Hall, Kristin M.. AU - Horvath, Tamara L.. AU - Abonour, Rafat. AU - Cornetta, Kenneth. AU - Srour, Edward F.. PY - 2006/4/1. Y1 - 2006/4/1. N2 - Objective. Many clinical gene therapy trials have described poor engraftment of retrovirally transduced CD34+ cells. Because engraftment is dependent upon successful homing of graft cells to the bone marrow (BM), we examined whether retroviral-mediated gene transfer (RMGT) induces a homing defect in CD34+ cells. Methods. Homing of fluorescently labeled human BM CD34+ cells transduced with three separate retroviral vectors (MFG-eGFP, LNC-eGFP, and LXSN) was assessed in nonobese diabetic/severe combined immunodeficient mice. Results. Homing of transduced CD34+ cells was significantly decreased 20 hours after transplantation compared with freshly isolated control and cultured untransduced control cells. Specifically, homing of GFP+ ...
The present invention relates to a method of amplifying in vitro stemcells. In this method hematopoietic CD34+ stem and progenitor cells are isolated from human bone marrow and contacted with endothelial cells. The contacted stem cells and endothelial cells are cultured in the presence of at least one cytokine in an amount sufficient to support amplification/expansion of the hematopoietic CD34+ stem and progenitor cells. This method produces increased yields of hematopoietic CD34+ stem and progenitor cells which can be used in human therapeutics.
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the Pub Med ID of your paper to get a coupon. ...
Background: CD31, PECAM-1 has been used as a marker for endothelial cells. However, recent data have indicated that CD31 is also expressed at an early developmental stage. We hypothesized that CD31 could serve as a comprehensive epitope to encircle various subsets of hemangioblastic cells in adult bone marrow (BM).. Methods and Results: A fraction of CD31+ cells of BM mononuclear cells in C57BL/6 mice co-expressed well known stem cell markers including c-kit, Sca-1, and flk-1. The expression levels of these markers were distinct when hematopoietic lineage positive cells were depleted (Lin−) from CD31+ cells. Moreover, Lin−CD31+ cells exclusively expressed genes characterizing pluripotency such as Oct4, Rex4, Nanog, and SSEA-1.A microarray revealed that CD31+ cells expressed multiple angiogenic genes compared to CD31− cells. In particular, only a CD31+ but not CD31− fraction gave rise to endothelial progenitor cells (EPCs) in a culture assay. To determine in vivo activity, we performed BM ...
TY - JOUR. T1 - Drosophila forkhead homologues are expressed in CD34+HLA-DR- primitive human hematopoietic progenitors. AU - Hromas, Robert. AU - Klemsz, Michael. AU - Amaravadi, Lakshmi. AU - Hufford, Tricia. AU - Huang, Irene. AU - Desai, Alpana. AU - Srour, Edward. AU - Bruno, Edward. AU - Hoffman, Ronald. PY - 1994. Y1 - 1994. N2 - The Forkhead gene (FKH) regulates morphogenesis in Drosophila. It is the prototype of a new family of transcriptional activators. We used the polymerase chain reaction (PCR) to analyze the expression pattern of this new transcriptional regulatory gene family in primitive hematopoeitic progenitors. Partially degenerate oligonucleotides to two conserved amino acid sequences of this family were used to prime a PCR amplification of cDNA synthesized from CD34+HLA-DR- hematopoietic cells. Known and novel FKH genes were found to be expressed in these cells.. AB - The Forkhead gene (FKH) regulates morphogenesis in Drosophila. It is the prototype of a new family of ...
AllCells offers a wide selection of human primary cells and related products including Bone Marrow CD34+ Stem/Progenitor Cells from our AllCells.com store.
The present invention relates to an antibody composition which contains antibodies specific for glycophorin A, CD3, CD24, CD16, CD14, and optionally CD45RA, CD38, CD36, CD38, CD56, CD2, CD19, CD66e, CD66b, and/or antibodies specific for antigens expressed on non-hematopoietic tumor cells. A process is also provided for enriching and recovering human hematopoietic progenitor cells and stem cells in a sample containing human hematopoietic differentiated, progenitor, and stem cells, and optionally tumor cells. The process involves reacting the sample with an antibody composition containing antibodies capable of binding to the antigens glycophorin A, CD3 CD24, CD16, and CD14, and optionally CD45RA, CD36, CD38, CD56, CD2, CD19, CD66e, CD66b, and/or antibodies specific for antigen expressed on non-hematopoietic tumor cells under conditions so that cell conjugates are formed between the antibodies and differentiated cells having the antigens glycophorin A, CD3 CD24, CD16, and CD14, and optionally CD45RA, CD38,
AllCells offers a wide selection of human primary cells and related products including Bone Marrow CD105+ Endothelial Cells from our AllCells.com store.
CD133 is a novel 5-transmembrane cell surface antigen with a molecular weight of 117 kDa. CD133/2 (AC141) antibodies recognize epitope 2 of the human CD133 antigen (CD133/2). In the hematopoietic system, CD133 expression is restricted to a subset of CD34bright stem and progenitor cells in human fetal liver, bone marrow, cord blood and peripheral blood. Additionally, CD133 is expressed by a small portion of CD34- cells in these tissues. The CD34+ CD133+ cell population, which includes CD34+ CD38- cells, was shown to be capable of repopulating NOD/SCID mice. Recently, CD133 has also been found to be expressed on endothelial precursor cells and fetal neural stem cells as well as on developing epithelium. The putative murine homologue, prominin, which is expressed on neuroepithelial and epithelial mouse cells, was identified. In contrast to the other CD133 clones, the clone AC141 shows cross-reactivity with the intracellular protein cytokeratin 18. - USA
CD133 is a novel 5-transmembrane cell surface antigen with a molecular weight of 117 kDa. CD133/2 (AC141) antibodies recognize epitope 2 of the human CD133 antigen (CD133/2). In the hematopoietic system, CD133 expression is restricted to a subset of CD34bright stem and progenitor cells in human fetal liver, bone marrow, cord blood and peripheral blood. Additionally, CD133 is expressed by a small portion of CD34- cells in these tissues. The CD34+ CD133+ cell population, which includes CD34+ CD38- cells, was shown to be capable of repopulating NOD/SCID mice. Recently, CD133 has also been found to be expressed on endothelial precursor cells and fetal neural stem cells as well as on developing epithelium. The putative murine homologue, prominin, which is expressed on neuroepithelial and epithelial mouse cells, was identified. In contrast to the other CD133 clones, the clone AC141 shows cross-reactivity with the intracellular protein cytokeratin 18. - USA
Regenerative strategies in the treatment of acute stroke may have great potential. Hematopoietic growth factors mobilize hematopoietic stem cells and may convey neuroprotective effects. We examined the safety, potential functional and structural chan
ABCell-Bio offers its CD133+ hematopoietic progenitors carefully isolated from umbilical cord blood, an excellent alternative source of Hematopoietic Stem Cells. Our CD133+ hematopoietic progenitors are subject to many quality controls, certifying their virologic compliance, performance, purity and viability. We can supply CD133 + cells with a purity above 95%.
in Transfusion (1998), 38(2), 199-208. BACKGROUND: A study of CD34+ cell selection and transplantation was carried out with particular emphasis on characteristics of short- and long-term hematopoietic recovery. STUDY DESIGN AND METHODS ... [more ▼]. BACKGROUND: A study of CD34+ cell selection and transplantation was carried out with particular emphasis on characteristics of short- and long-term hematopoietic recovery. STUDY DESIGN AND METHODS: Peripheral blood stem and progenitor cells (PBPCs) were collected from 32 patients, and 17 CD34+ cell-selection procedures were carried out in 15 of the 32. One patient in whom two procedures failed to provide 1 x 10(6) CD34+ cells per kg was excluded from further analysis. After conditioning, patients received CD34+ cells (n = 10, CD34 group) or unmanipulated (n = 17, PBPC group) PBPCs containing equivalent amounts of CD34+ cells or progenitors. RESULTS: The yield of CD34+ cells was 53 percent (18-100) with a purity of 63 percent (49-82). The CD34+ ...
Hematopoietic stem/progenitor cells (HSPCs) maintain the hematopoietic system by balancing their self-renewal and differentiation events. Hematopoietic stem cells also migrate to various sites and interact with their specific microenvironment to maintain the integrity of the system. Rho GTPases have been found to control the migration of hematopoietic cells and other cell types. Although the role of RAC1, RAC2 and CDC42 has been studied, the role of RHOA in human hematopoietic stem cells is unclear. By utilizing constitutively active and dominant negative RHOA, we show that RHOA negatively regulates both in vitro and in vivo migration and dominant negative RHOA significantly increased the migration potential of human HSC/HPCs. Active RHOA expression favors the retention of hematopoietic stem/progenitor cells in the niche rather than migration and was found to lock the cells in the G0 cell cycle phase thereby affecting their long-term self-renewal potential. The current study demonstrates that down
Recent developments of surrogate assays for human hematopoietic stem cells (HSC) have facilitated efforts at improving HSC gene transfer efficiency. Through the use of xenograft transplantation models, such as nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice, successful oncoretroviral gene transfer to transplantable hematopoietic cells has been achieved. However, because of the low frequency and/or homing efficiency of SCID repopulating cells (SRC) in bone marrow (BM), studies have primarily focused on cord blood (CB). The recently developed extended (| 60 days) long-term culture-initiating cell (ELTC-IC) assay detects an infrequent and highly quiescent candidate stem cell population in BM as well as CB of the CD34(+)CD38(-) phenotype. Although these characteristics suggest that ELTC-IC and SRC might be closely related, attempts to oncoretrovirally transduce ELTC-IC have been unsuccessful. Here, recently developed conditions (high concentrations of SCF + FL + Tpo in serum-free medium)
The only curative therapy for sickle cell disease (SCD) is allogeneic hematopoietic stem cell (HSC) transplantation. Gene therapy approaches for autologous HSC transplantation are being developed. Although earlier engraftment is seen when cells from GCSF-mobilized blood are transplanted than when bone marrow is transplanted, administration of GCSF to patients with SCD can cause significant morbidity. We tested whether primitive hematopoietic progenitors are spontaneously mobilized in the blood of patients with SCD during acute crisis (AC-SCD patients). The frequency of myeloid-lymphoid-initiating cells (ML-ICs) and SCID-repopulating cells (SRCs) was significantly higher in blood from AC-SCD patients than in blood from patients with steady-state SCD or from normal donors. The presence of SRCs in peripheral blood was not associated with detection of long-term culture-initiating cells, consistent with the notion that SRCs are more primitive than long-term culture-initiating cells. As ML-ICs and ...
Human umbilical cord blood derived CD34+ stem cells are reported to mediate therapeutic effects in stroke animal models. Estrogen was known to protect against ischemic injury. The present study wished to investigate whether the protective effect of CD34+ cells against ischemic injury can be reinforced with complemental estradiol treatment in female ovariectomized rat and its possible mechanism. Experiment 1 was to determine the best optimal timing of CD34+ cell treatment for the neuroprotective effect after 60-min middle cerebral artery occlusion (MCAO). Experiment 2 was to evaluate the adjuvant effect of 17β-estradiol on CD34+ cell neuroprotection after MCAO. Experiment 1 showed intravenous infusion with CD34+ cells before MCAO (pre-treatment) caused less infarction size than those infused after MCAO (post-treatment) on 7T magnetic resonance T2-weighted images. Experiment 2 revealed infarction size was most significantly reduced after CD34+ + estradiol pre-treatment. When compared with no treatment
Since tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, and transforming growth factor (TGF)-beta have all been shown to be specific inhibitors of early human hematopoiesis, we wanted to investigate the interactions of these three cytokines on very primitive human adult bone marrow CD34++CD38- hematopoietic progenitor cells, using a pre-colony-forming cell (pre-CFC) assay, which detects the effects of these cytokines on the initial phases of the differentiation of these primitive progenitors, which are unresponsive to interleukin (IL) 3 alone. Surprisingly, TNF-alpha was a very potent stimulator of the proliferation of CD34++CD38- cells and was the most potent synergistic factor for the IL-3-induced proliferation of these cells of all cytokines tested (IL-1, IL-6, granulocyte colony-stimulating factor, kit ligand). TNF-alpha was the only cytokine that, as a single added factor, induced substantial proliferation in CD34++CD38- cells in the presence of IL-3, except for kit ligand, which ...
Toda la información sobre las últimas publicaciones científicas de la Clínica Universidad de Navarra. Primitive long-term culture initiating cells (LTC-ICs) in granulocyte colony-stimulating factor mobilized peripheral blood progenitor cells have similar potential for ex vivo expansion as primitive LTC-ICs in steady state bone marrow
This study enumerated CD45hi/CD34+ and CD45hi/CD133+ human hematopoietic stem cells (HSC) and granulocyte-monocyte colony forming (GM-CFC) progenitor cells in blood and trochanteric and femoral bone marrow in 233 individuals. (SP) multipotential HSC, that are the precursors of CD45hi/CD133+ and CD45hi/CD34+, decline with age. Potentially the increases in stem cell frequencies in the intermediate compartment between SP and GM progenitor cells observed in this study represent a compensatory increase for the loss of more potent members of the HSC hierarchy. testis cause a decline in germ cell self-renewal 40. To test the hypothesis, 233 human subjects, of ages between 21 and 88 years, undergoing hip replacement surgery were enrolled in an IRB approved research which enumerated the SP HSC, Compact disc34+ and Compact disc133+ HSC by movement cytometry and myeloid colony developing cells (GM-CFC) in tradition through the bone marrow from the trochanteric area from the femoral diaphysis and femoral ...
Megan D. Hoban, Gregory J. Cost, Matthew C. Mendel, Zulema Romero, Michael L. Kaufman, Alok V. Joglekar, Michelle Ho, Dianne Lumaquin, David Gray, Georgia R. Lill, Aaron R. Cooper, Fabrizia Urbinati, Shantha Senadheera, Allen Zhu, Pei-Qi Liu, David E. Paschon, Lei Zhang, Edward J. Rebar, Andrew Wilber, Xiaoyan Wang, Philip D. Gregory, Michael C. Holmes, Andreas Reik, Roger P. Hollis, Donald B. Kohn. ...
Holmes, T., Yan, F., Ko, K.-H., Nordon, R., Song, E., OBrien, T. A. and Dolnikov, A. (2012), Ex vivo expansion of cord blood progenitors impairs their short-term and long-term repopulating activity associated with transcriptional dysregulation of signalling networks. Cell Proliferation, 45: 266-278. doi: 10.1111/j.1365-2184.2012.00813.x ...
Expression of Thy-1 on hematopoietic cells from human fetal liver (FL), cord blood (CB), and bone marrow (BM) was studied with a novel anti-Thy-1 antibody, 5E10. Specificity of 5E10 for human Thy-1 was demonstrated by immunoprecipitation of a 25-35-kD molecule, and the sequence of a cDNA that was cloned by immunoselection of COS cells transfected with a cDNA library derived from a 5E10+ cell line. Two- and three-color immunofluorescence staining experiments revealed that the Thy-1 expression is restricted to, an average, 1-4% of FL, CB, and BM cells, and binding to these cell types is essentially restricted to a very small subset of lymphoid cells and approximately 25% of CD34+ cells. Thy-1+ CD34+ cells were further characterized as CD38lo/CD45RO+/CD45RA-/CD71lo/c-kit(lo) and rhodamine 123dull. When CD34+ cells were sorted on the basis of Thy-1 expression, the majority of clonogenic cells were recovered in the CD34+Thy-1- fraction, whereas the majority of cells capable of producing myeloid ...
Hematopoietic progenitor cells, cord blood is used for blood cell transplantation procedures in patients with disorders that affect blood production. This medicine is derived from human blood that is collected from the umbilical cord and placenta. The hematopoietic progenitor cells go to the bone marrow where they become red blood cells, white blood cells, or platelets. These cells enter the blood stream and help restore low blood counts in patients with blood disorders. ...
Abstract. Evidence has been provided recently that shows that high concentrations of cytokines can fulfill functions previously attributed to stromal cells, su
AABB Hematopoietic Progenitor Cell (HPC) activities include educational programs, publications and accreditation for HPC programs.. The list of AABB Accredited HPC Facilities specifies those HPC facilities, in the US and throughout the world, which have attained AABB accreditation. These facilities are responsible for procuring, processing and storing hematopoietic progenitor cells that can be used for transplantation.. ...
O CD34 (Cluster of Differentiation 34) é uma molécula presente na superfície de determinadas células do organismo humano. É uma glicoproteína e funciona como fator de adesão celular. Também atua mediando a ligação de células-tronco hematopoéticas à matriz extracelular ou às células do estroma. Utiliza-se a denominação CD34 também para identificar o gene que codifica tal proteína. «Entrez Gene: CD34 CD34 molecule» Simmons DL, Satterthwaite AB, Tenen DG, Seed B (1 de janeiro de 1992). «Molecular cloning of a cDNA encoding CD34, a sialomucin of human hematopoietic stem cells». J. Immunol. 148 (1): 267-71. PMID 1370171 !CS1 manut: Nomes múltiplos: lista de autores (link) Satterthwaite AB, Burn TC, Le Beau MM, Tenen DG (1992). «Structure of the gene encoding CD34, a human hematopoietic stem cell antigen». Genomics. 12 (4): 788-94. PMID 1374051. doi:10.1016/0888-7543(92)90310-O A referência emprega parâmetros obsoletos ,month= (ajuda) !CS1 manut: Nomes múltiplos: lista de ...
The CD109 antigen is a monomeric glycosyl phosphatidylinositol (GPI)-linked glycoprotein of 170 kDa that contains several N-linked endoglycosidase H-sensitive hybrid-type glycans but no O-linked glycan. It has been reported as a novel member of the α2 macroglobulin (α2M) / C3, C4, C5 family of thioester-containing proteins. The CD109 antigen is found on vascular endothelial cells, some epithelial cells, activated, but not resting, T-cells, activated, but not resting, platelets, leukemic megakaryoblasts and a subset of bone marrow CD34+ cells. This antigen is not expressed on fresh peripheral blood lymphocytes (PBL). Poorly differentiated (CD34+, TdT+, CD7+) T-acute leukemias and rare cases of chronic myeloid leukemia in megakaryoblast crisis express the CD109 antigen. Furthermore, megakaryoblastoid cell lines (MO7e, MOLM-1) are CD109+. The CD109 antigen, strongly expressed on KG1a cell line with 20,000 binding sites per cell, may represent a very early marker for hematopoietic cells committed ...
Detailed drug Information for hematopoietic progenitor cells, cord blood Intravenous. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details ...
Research proven mouse monoclonal CD34 antibody. Excellent marker for hematopoietic progenitors and stem cells. CD34 protein is involved in differentiating HPCs into certain types of neurons. Also useful for studying endothelial cells, angigogensis and tumorigenesis. Designed for immunohistochemisitry and related applications. IHC image available.
Research proven mouse monoclonal CD34 antibody. Excellent marker for hematopoietic progenitors and stem cells. CD34 protein is involved in differentiating HPCs into certain types of neurons. Also useful for studying endothelial cells, angigogensis and tumorigenesis. Designed for immunohistochemisitry and related applications. IHC image available.
Abrupt occlusion of coronary arteries causes MI, which leads to massive cardiomyocyte loss and consequently deterioration of cardiac function because cardiomyocytes have severely limited capacity to be divided and thus replace the damaged tissue. Progressive heart failure is a major cause of death or frequent hospitalization in patients after MI. Although MI is classified as vascular (coronary artery) disease, therapeutic strategies should be focused on regenerating not only blood vessels but also cardiac muscle to improve the poor prognosis of the disease.. Compelling evidence suggests that transplantation of bone marrow-derived CD34+ cells or cultured EPC-enriched population contributes to preservation of LV function after MI through enhancing ischemic neovascularization.10-12 The mechanism of this therapeutic effect was previously considered to be incorporation, differentiation, and proliferation of EPCs for new blood vessel formation.9,11,26 Recently, Badorff et al27 reported in vitro ...
The CD123 antigen, alias Interleukin-3 alpha receptor (IL-3Rα), belongs to the cytokine receptor family. It is constitutively expressed by committed hematopoietic stem / progenitor cells, by most of the myeloid lineage (CD13+, CD14+, CD33+, CD15low), and by some CD19+ cells, it is absent from CD3+ cells ...
PRC2 Inhibition Counteracts the Culture-Associated Loss of Engraftment Potential of Human Cord Blood-Derived Hematopoietic Stem and Progenitor Cells
Assisted Reproductive Technologies and Haematopoietic stem cells Improvements for Quality and Safety throughout Europe ̶ an European Joint Action ...c
Laboratory equipment supplier for research and industry needs. Access now to the largest scientific products database in our online store.
Combined Growth Factors Enhance the Angiogenic Potential of Human Cord Blood-Derived Mononuclear Cells Transplanted to Ischemic Limbs
Gentaur molecular products has all kinds of products like :search , Alpha Dia \ Anti_Human CD45RA_PE_Cy5_conjugate \ CD45RAPC-100 for more molecular products just contact us
Gentaur molecular products has all kinds of products like :search , Alpha Dia \ Anti_Human CD9_PE_Cy5_conjugate \ CD09PC-25 for more molecular products just contact us
We have studied Rac signal transduction in human cord-blood (CB) and acute myeloid leukemia (AML) CD34+ cells and determined that Rac proteins are critically involved in the interaction between human stem/progenitor cells and stroma. Constitutive activation of Rac signaling was achieved by retroviral introduction of Rac1-V12 into CB-derived CD34+ cells, while inhibition of Rac signaling was established by retroviral introduction of dominant negative Rac1-N17 or by utilizing the Rac inhibitor NSC23766. Inhibition of Rac signaling resulted in a proliferative disadvantage of CB-CD34+ cells when cultured on MS5 stromal cells. Cells were severely disturbed in their migration towards and direct association with MS5 stroma when Rac signaling was inhibited. The Long Term Culture-Initiating Cells (LTC-ICs) migrated underneath the stromal MS5 layer within 24 hrs after plating, and similar results were obtained for about 50% of the Colony Forming Cells (CFCs). However, transient inhibition of Rac signaling ...
BACKGROUND: Human umbilical cord blood (HUCB) is a possible alternative to bone marrow (BM) and mobilized peripheral blood (PB) for transplantation of hematopoietic progenitors. The aim of this study was to evaluate the phenotypic profile of CD34+ progenitors present in HUCB. MATERIALS AND METHODS: A flow cytometric analysis was performed on 20 HUCB samples, using a large panel of monoclonal antibodies recognizing different lineage or activation antigens, in double labeling with CD34. RESULTS: A toal of 13,897 +/- 2,529 cells/microL, 0.84 +/- 0.83% of which were CD34+, was found. The large majority of CD34+ cells were committed toward initial myeloid differentiation (CD33+, CD13+) and expressed the transferrin receptor (CD71). A substantial proportion of these cells (about 40%) co-expressed CD45RA and CD117, while a very small number displayed markers of advanced myeloid commitment, such as CD14, CD15 and CD41 (less than 2%), or those of lymphoid differentiation: CD2, CD5, CD7, CD10 and CD19 ...
Umbilical cord blood (UCB) is increasingly being used for human hematopoietic stem cell (HSC) transplantation in children but often requires pooling multiple cords to obtain sufficient numbers for transplantation in adults. To overcome this limitation, we have used an ex vivo two-week culture system to expand the number of hematopoietic CD34(+) cells in cord blood. To assess the in vivo function of these expanded CD34(+) cells, cultured human UCB containing 1 x 10(6) CD34(+) cells were transplanted into conditioned NOD-scid IL2rgamma(null) mice. The expanded CD34(+) cells displayed short- and long-term repopulating cell activity. The cultured human cells differentiated into myeloid, B-lymphoid, and erythroid lineages, but not T lymphocytes. Administration of human recombinant TNFalpha to recipient mice immediately prior to transplantation promoted human thymocyte and T-cell development. These T cells proliferated vigorously in response to TCR cross-linking by anti-CD3 antibody. Engrafted
Thrombopoietin (Tpo) is a primary regulator of megakaryocyte and platelet production. However, studies in c-mpl-deficient mice suggest that Tpo might also play an important role in early hemopoiesis. Here, the direct ability of Tpo to stimulate stroma-independent growth, multilineage differentiation, and progenitor cell expansion from single primitive CD34+ CD38- human bone marrow cells was investigated. Tpo alone stimulated limited clonal growth, but synergized with c-kit ligand (KL), flt3 ligand (FL), or IL-3 to potently enhance clonogenic growth. Whereas KL and FL in combination stimulated the clonal growth of only 3% of CD34+ CD38- cells, 40% of CD34+ CD38- cells were recruited by KL+FL+Tpo, demonstrating that Tpo promotes the growth of a high fraction of CD34+ CD38- progenitor cells. Additional cytokines (IL-3, IL-6, and erythropoietin (Epo)) did not significantly enhance clonal growth above that observed in response to KL+FL+Tpo. In contrast, Tpo enhanced clonogenic growth in response to KL+FL+IL
De Wynter, E.A., Buck, D., Hart, C., Heywood, R., Coutinho, L.H., Clayton, A., Rafferty, J.A., Burt, D., Guenechea, G., Bueren, J.A., Gagen, D., Fairbairn, L.J., Lord, B.I. & Testa, N.G. (1998) CD34+AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors. Stem Cells, 16, 387-396. ...
|p|The LEGENDplex™ Human Hematopoietic Stem Cell Panel Detection Antibodies contains 12 anti-human antibodies against IL-6, FLT3L, GM-CSF, IL-3, IL-34, IL-11, SCF, LIF, CXCL12 (SDF-1), IL-15, M-CSF, and IL-7. This Detection cocktail is recommended for use with the following in Mix and Match assays:|
...Putnam Valley NY. (Mar. 6 2014) When human umbilical cord blood cel...The study will be published in a future issue of Cell Transplantati... Myocardial infarction induced by coronary artery disease is one of th...According to the authors stem cell therapy for myocardial repair has ...,Transplanted,human,umbilical,cord,blood,cells,improved,heart,function,in,rat,model,of,MI,biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters
Although pharmacological methods for treating AD have been discovered, none significantly delay the progression of the disease. However, cell transplantation research using animals modeled with AD has indicated that human umbilical cord blood cells (HUCBCs) can ameliorate some cognitive deficits and reduce the effects of the amyloid-beta (Aβ) plaques, one of the physiological hallmarks of AD, comprised of peptides of 36-43 amino acids. However, the role that HUCBCs play in Aβ clearance has yet to be elucidated ...
Potential Stem Cell Therapy for HIV Reported From Nature Biotech An advance online article from Nature Biotechnology reports the creation of genetically modified human hematopoietic stem/progenitor cells which when injected and engrafted in mice confer some resistance to HIV. Specifically, Holt et al disrupted CCR5, the major HIV-1 co-receptor using engineered zinc-finger nucleases (ZFNs) and compared to control mice, the mice which received such cells showed significantly lower HIV-1 levels.
In this issue, Singh et al. set out to decipher the mechanism by which CD26 relays G-CSF-induced HSPC mobilization (16, 17). This was achieved by performing sophisticated experiments to determine the extent to which CD26 expression by hematopoietic cells or by stromal cells in the BM microenvironment is essential for the stem cell mobilization process (1). Contrary to the prior hypothesis suggesting that CXCL12 cleavage by hematopoietic CD26 promotes HSPC migration out of the BM, Singh and colleagues showed that hematopoietic expression of CD26 is not essential for HSPC mobilization. Moreover, CD26 expression was reduced in mobilized HSPCs, and deletion of CD26 in murine HSPCs did not alter HSPC mobilization in a WT environment (1). These unexpected results align with recent reports indicating that CD26 truncates inflammatory cytokines into a nonactive form (18, 19) and, as such, may interfere with the hematopoietic response during alert and stress conditions. However, CD26 expression by niche ...
AIDS patients who develop lymphoma are often treated with transplanted hematopoietic progenitor cells. As a first step in developing a hematopoietic cell-based gene therapy treatment, four patients undergoing treatment with these transplanted cells were also given gene-modified peripheral blood-derived (CD34+) hematopoietic progenitor cells expressing three RNA-based anti-HIV moieties (tat/rev short hairpin RNA, TAR decoy, and CCR5 ribozyme). In vitro analysis of these gene-modified cells showed no differences in their hematopoietic potential compared with nontransduced cells. In vitro estimates of successful expression of the anti-HIV moieties were initially as high as 22% but declined to ~1% over 4 weeks of culture. Ethical study design required that patients be transplanted with both gene-modified and unmanipulated hematopoietic progenitor cells obtained from the patient by apheresis. Transfected cells were successfully engrafted in all four infused patients by day 11, and there were no ...
The hemangioblast - the cell that originated endothelial and hematopoietic cells in the embryo - is a transient cell type that develops early and disappears quickly during embryonic development. In human postnatal life, CD133+, CD34+, or CD34+KDR+ cell subsets in bone marrow, peripheral blood and cord blood possess the functional activity of hemangioblasts and are capable to differentiate into both hematopoietic and endothelial cells. We are comparing the functional properties and gene expression profiles of pure populations of bone marrow, peripheral blood, and umbilical cord blood CD133+, CD34+, CD34+KDR+, CD133+KDR+, CD34-CD133+, CD34+CD133+ cells to study their capacity to form hematopoietic colonies on long term culture (LTC-IC), and endothelial colonies in matrigel plaques. Next, we will examine the gene expression profile of CD133+ and CD34+ cells in order to characterize them. We also intend to transplant these cells in animal models of hematopoietic and endothelial injury to evaluate ...
This study aimed to correlate blood Flt3-ligand (FL) concentration with CD34+ cell number in blood and bone marrow (BM) during granulocyte colony-stimulating factor (G-CSF) mobilization. Nonhuman primates were injected with 10 μg/kg of G-CSF (Lenograstim) daily over a period of 5 days. Daily blood sampling and repeated BM sampling showed that FL concentration before mobilization was negatively correlated to the absolute number of BM CD34+ cells, but also to the number of G-CSF-mobilized CD34+ cells on days 3-5 of treatment. This showed that FL concentration in the blood reflected BM status before mobilization, and suggested that this parameter could be used as a predictive indicator of G-CSF-induced CD34+ cell mobilization ...
Background aims. Cord blood is considered to be a superior source of hematopoietic stem and progenitor cells for transplantation, but clinical use is limited primarily because of the low numbers of cells harvested. Ex vivo expansion has the potential to provide a safe, effective means of increasing cell numbers. However, an absence of consensus regarding optimum expansion conditions prevents standard implementation. Many studies lack clinical applicability, or have failed to investigate the combinational effects of different parameters ...
PRIMARY OBJECTIVES:. I. Assess the safety of infusing off-the-shelf non-human leukocyte antigen (HLA) matched expanded cord blood cells as supportive care following administration of fludarabine phosphate, cytarabine, and filgrastim (FLAG) consolidation or reinduction chemotherapy in pediatric and young adult patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage.. SECONDARY OBJECTIVES:. I. Assess the kinetics of autologous recovery when compared to historical cohorts.. II. Assess the ability of the product to provide transient myeloid engraftment/recovery.. III. Examine the in vivo persistence of the ex vivo expanded cord blood cells by determining the kinetics and durability of potential engraftment.. IV. Develop understanding of the underlying immune interaction between the patient (host) and the infused expanded cord blood cells (donor) by performing in vitro analyses to assess host-mediated rejection of the non HLA-matched expanded cells.. V. Estimate the ...
Hematopoietic progenitor cell antigen CD34 also known as CD34 antigen is a protein that in humans is encoded by the CD34 gene. CD34 is a cluster of differentiation first described independently by Civin et al. and Tindle et al. in a cell surface glycoprotein and functions as a cell-cell adhesion factor. It may also mediate the attachment of stem cells to bone marrow extracellular matrix or directly to stromal cells. The CD34 protein is a member of a family of single-pass transmembrane sialomucin proteins that show expression on early hematopoietic and vascular-associated tissue. However, little is known about its exact function. CD34 is also an important adhesion molecule and is required for T cells to enter lymph nodes. It is expressed on lymph node endothelia, whereas the L-selectin to which it binds is on the T cell. Conversely, under other circumstances CD34 has been shown to act as molecular "Teflon" and block mast cell, eosinophil and dendritic cell precursor adhesion, and to facilitate ...
Introduction: We previously demonstrated peripheral mobilisation of CD133+/CD45+ hematopoietic stem cells after extended forms of clinical hepatectomy. In this study we correlated peripheral CD133+/CD45+ cell mobilisation with the extend of resected liver volume and its regain, with paracrine factors like hepatic growth factor (HGF), CXCL12 (SDF-1) and alpha feto protein (AFP).. Materials and methods: Peripheral progenitor mobilisation was investigated by FACS-analyses in 30 hepatectomy patients. Exact extend of liver volume loss and regain by day-21 after hepatic resection was determined by CTscan volumetry. 20 patients with resection volume of less than 20% (groupA;n=20) were contrasted to 10 patients with a resection extend of 30-67% (groupB;n=10). Mobilising capacity of HGF and SDF-1 for CD133+/CD45+ BMSCs was investigated in two migration assays (UnderAgarose ChemotaxisAssay, BoydenChamber TranswellAssay).. Results: In groupB we observed increased levels of HGF, SDF-1 in the first 6h and of ...
Clinical Grade Non-Transfusable Mobilized Peripheral Blood CD19 Depleted Cells, G-CSF, Frozen, Human B cells are lymphocytes that are characterized by the expression of CD19 on the cell surface. These cells are one of the main cell types involved in the
Endothelial progenitor cells (EPC) are immature cells present in the blood, where their physiological role is the maintenance of vascular integrity. Each batch of cells produced by ABCell-Bio comes from a single donor. The number of cells in our standard packaging is 500,000 cells guaranteed at passage 3 after thawing in your laboratory. All our batches are subjected to high quality controls allow us to guarantee you efficient cells after thawing. Each EPC batch is negative for HIV-1/2, hepatitis B and hepatitis C.
Circulating endothelial progenitor cells (EPCs) in adult human peripheral blood were originally identified in 1997 by Asahara et al
The normal CD4 count range is 500-1500 and the normal CD4 percentage is 35-50%. The lower the CD4 percent and count, the worse off the immune system...
Human CD14 monocytes from peripheral blood of healthy adult donors. Our primary human monocytes are uncultured and have purity |95%.
Strating the activities of the host and sustaining homeostasis. The plasticity of hematopoietic progenitor cells in the BM bestows upon them the ultimate power
Here are the highlights from the current issue of Development: A new niche for human HSCs Human haematopoiesis occurs at various anatomical sites th
|!--StartFragment--|CD33 levels in childhood AML may help further delineate risk groups, and have implications for anti-CD33 targeted therapies in the future
Blood, 2001; 98 (12) doi:. Authors: Zaucha J M, Gooley T, Bensinger W I, Heimfeld S, Chauncey T R Zaucha J M, Gooley T, Bensinger W I, Heimfeld S, Chauncey T R, Zaucha R, Martin P J, Flowers M E, Storek J, Georges G, Storb R, Torok-Storb B et al.(7) Affiliation: Fred Hutchinson Cancer Research Center, United States Abstract: A retrospective analysis of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cell (G-PBMC) products harvested from healthy donors indicates significant variability in both the absolute number and relative proportion of CD34, CD3, and CD14 cells obtained. This report examined whether variations in the cellular composition of G-PBMC products correlated with clinical outcomes after myeloablative allogeneic transplantation. The numbers of CD34, CD3, and CD14 cells infused into 181 human leukocyte antigen (HLA)-identical sibling recipients were analyzed with respect to tempo of engraftment, acute graft-versus-host-disease (GVHD), clinical ...
Results Culture-expanded amnion-derived adherent cells expressed mesenchymal stem cell markers and HLA-ABC molecules and could differentiate into osteoblasts, adipocytes and chondrocyte-like cells, indicating that the cells have the characteristics of mesenchymal stem cells. The Lin-CD34+ cells purified from the frozen umbilical cord blood were strongly positive for HLA-ABC, and contained a large number of hematopoietic stem cells. When the Lin-CD34+ cells were cultured on the autologous (MHC-matched) or MHC-mismatched amnion-derived adherent cells in short-term assays (hematopoietic stem cell-proliferation) and long-term culture-initiating cell assays, greater expansion of the Lin-CD34+ cells was observed in the MHC-matched combination than in MHC-mismatched combinations. The concentration of granulocyte-macrophage colony-stimulating factor in the culture supernatants of the long-term culture-initiating cell assays was significantly higher in the MHC-matched combination than in MHC-mismatched ...
We tested the effects of DP on erythroid and granulocyte-macrophage colony formation in progenitor cells from preterm infants and adults. The concentrations of DP included in the culture dishes ranged from 10−6 M to 10−9M. Studies on the pharmacokinetics of DP in preterm infants have shown that the plasma concentrations reached following DP administrations are in the order of magnitude of 10−6 M to 10−8M.7 It is not known, however, whether these concentrations will be achieved in the bone marrow, nor whether interactions with other hormones or mediators in the bone milieu will influence the effect of DP on haematopoietic progenitors. In our experimental conditions DP showed a dose dependent inhibitory effect on both erythroid and granulocyte-macrophage colonies derived from progenitor cells of preterm infants. CFU-E colonies were the most affected, with significant reductions observed at all concentrations of DP. This profound reduction in erythroid colonies was not apparent with bone ...
TY - JOUR. T1 - Differential gene expression underlying the functional distinctions of primary human CD34+ hematopoietic stem and progenitor cells from peripheral blood and bone marrow. AU - Steidl, Ulrich G.. AU - Kronenwett, Ralf. AU - Haas, Rainer. PY - 2003. Y1 - 2003. N2 - The restorative capacity of human CD34+ hematopoietic cells is clinically used in the autologous and allogeneic transplant setting to support cytotoxic therapy. We examined gene expression patterns of highly enriched bone marrow CD34+ (BM-CD34+) or G-CSF-mobilized peripheral blood CD34+ (PB-CD34+) cells by cDNA array technology, quantitative real-time RT-PCR, and flow cytometry, to identify molecular causes underlying the functional differences between circulating and sedentary hematopoietic stem and progenitor cells. The greater cell cycle and DNA synthesis activity of BM-CD34+ compared to PB-CD34+ cells was reflected by the 2- to 5-fold higher expression of 9 genes involved in cell cycle, 11 genes regulating DNA ...
INTRODUCTION. Zebrafish maintains a remarkably higher ability than mammals to repair complex tissues after injury, including the heart and the central nervous system. For this reason, zebrafish embryos and their stem cells have been increasingly studied to unravel the molecular mechanisms underlying such regenerative potential, or to dissect evolutionary conserved pathways that may account for the regenerative action afforded by stem cells across different species.. Transplantation of human cord blood-derived CD34+ (hCD34+) cells into pregastrulation zebrafish embryos revealed that these human cells cosegregated with presumptive zebrafish hemangioblasts, being involved in early development of the embryonic vasculature of the recipient 1. Conversely, postgastrulation transplant resulted in the recruitment of hCD34+ cells into developing vessels, where their biology was mainly shifted to a paracrine action 2. These human cells were also found to accelerate vascular repair in adult zebrafish, after ...
TY - JOUR. T1 - Genetically modified hematopoietic stem/progenitor cells that produce IL-10-secreting regulatory T cells. AU - Ng, Sze Ling. AU - Leno-Duran, Ester. AU - Samanta, Dibyendu. AU - Almo, Steven C.. AU - Strominger, Jack L.. PY - 2019/2/12. Y1 - 2019/2/12. N2 - Random amino acid copolymers used in the treatment of multiple sclerosis in man or experimental autoimmune encephalomyelitis (EAE) in mice [poly(Y,E,A,K) n , known as Copaxone, and poly(Y,F,A,K) n ] function at least in part by generation of IL-10-secreting regulatory T cells that mediate bystander immunosuppression. The mechanism through which these copolymers induce Tregs is unknown. To investigate this question, four previously described Vα3.2 Vβ14 T cell receptor (TCR) cDNAs, the dominant clonotype generated in splenocytes after immunization of SJL mice, that differed only in their CDR3 sequences were utilized to generate retrogenic mice. The high-level production of IL-10 as well as IL-5 and small amounts of the related ...
This is the first etiopathogenesis study of BNP which assesses the functionality of BM-HPCs. The results shown here demonstrate that BNP was induced in the challenge animals and that functional damage to the hematopoietic progenitor cells was apparent prior to the development of clinical signs, gross or histopathological lesions. As early as 24 hours after colostrum intake, the CFUs-GEMM were compromised in their colony forming ability and by day 6 the number of all CFU types was markedly reduced. This supports the hypothesis that the main target cell is the pluripotent hematopoietic progenitor cell. In addition, this study further demonstrates that the more differentiated cells (CFU-E and CFU-GM precursors) present in the bone marrow are apparently not compromised at 24 hours post-colostrum ingestion.. Lymphopenia post-colostral challenge has been previously observed [9, 10, 12]; therefore in this study we attempted to determine whether a specific subset of peripheral blood mononuclear cells ...
To determine whether the early CAFCs induced by STAT5A(1*6) represent true HSCs, a variety of assays were undertaken. First, transduced CB CD34+ cells were sorted into GFP+/CD38low and GFP+/CD38high populations, which were analyzed for CAFC activity on MS5 under limiting dilution conditions. As indicated in Fig. 4 E, most of the CAFCs at day 10 arose from the CD38low population with a frequency of 13.8%, whereas the CD38high population contained some CAFCs at a frequency of 4.5%. Importantly, only the CAFCs generated by the GFP+/CD38low population gave rise to secondary CAFCs when plated onto fresh MS5 stroma, whereas the CAFCs generated from the GFP+/CD38high population did not (Fig. 4 E). Differentiated progeny from secondary CAFCs from the GFP+/CD38low population was monitored by flow cytometry and cytospins. Secondary CAFCs predominantly gave rise to erythroid cells and some myeloid cells (not depicted; see also Fig. 5). Furthermore, day 10 CAFCs were plated in methylcellulose to determine ...
BackgroundAmyotrophic Lateral Sclerosis (ALS) is a multicausal disease characterized by motor neuron degeneration in the spinal cord and brain. Cell therapy may be a promising new treatment for this devastating disorder. We recently showed that a single low dose (106 cells) of mononuclear human umbilical cord blood (MNC hUCB) cells administered intravenously to G93A mice delayed symptom progression and modestly prolonged lifespan. The aim of this pre-clinical translation study is to optimize the dose of MNC hUCB cells to retard disease progression in G93A mice. Three different doses of MNC hUCB cells, 10×106, 25×106 and 50×106, were administered intravenously into pre-symptomatic G93A mice. Motor function tests and various assays to determine cell effects were performed on these mice.Methodology/Principal FindingsOur results showed that a cell dose of 25×106 cells significantly increased lifespan of mice by 20-25% and delayed disease progression by 15%. The most beneficial effect on decreasing pro
Humanized mice engrafted only with human hematopoietic stem cell (HSC) do not develop fully functional T-cells. The BLT mouse model, which consists of co-implanting HSC from fetal liver with autologous fetal thymic tissue, was developed to promote an optimal T-cell reconstitution and maturation. However, access to human fetal tissues is challenging both from the ethical point of view and logistic. The goal of our study was to find an alternative to the use of fetal tissues to create a humanized mouse model with functional T-cells. Methods. We used pediatric thymus excised during cardiac surgeries (CS thymus) combined with umbilical cord blood CD34+ cells (CCST mice). CS thymuses pieces were implanted in the quadriceps of an NSG mouse, after being put in culture Results. CCST mice exhibited a significant engraftment of T-cells, compared to humanized mice without thymus (p,0.0001). T-cells from both CCST and BLT mice showed a similar function as evaluated by proliferation assays upon PHA ...
Our studies identify a novel subset of circulating human progenitor cells, that can be expanded in vitro to large numbers, are capable to differentiate into all 3 distinct cardiovascular cell lineages in vitro and in vivo, secrete proangiogenic and cardioprotective factors, and mediate significant functional improvements after therapeutic administration in models of ischemia and infarction, specifically when transduced with Sox2.. Marker expression by the isolated cells is clearly distinct from all subsets of hematopoietic or endothelial progenitor cells described so far, as shown by the absence of CD45, CD34, CD133, CXCR4 and myeloid markers, such as CD14 in bulk cultures and in single cell-derived colonies. Whereas the expression of mesenchymal markers is shared by bone marrow-derived and blood-derived MSCs and multipotent adult progenitor cells, the very high expression of the endothelial marker KDR and Tie2 is unique for the circulating cells isolated in the present study. Moreover, ...
http://www.ncbi.nlm.nih.gov/pubmed/19208786 We investigated whether the human placenta contributes to embryonic and fetal hematopoietic development. Two cell populations--CD34(++)CD45(low) and CD34( +)CD45(low)--were found in chorionic villi. CD34(++) CD45(low) cells display many markers that are characteristic of multipotent primitive hematopoietic progenitors and hematopoietic stem cells. Clonogenic in vitro assays showed that CD34(++)CD45( low) cells contained colony-forming units-culture with myeloid and erythroid potential and differentiated into CD56(+) natural killer cells and CD19(+) B cells in culture. CD34(+)CD45(low) cells were mostly enriched in erythroid- and myeloid-committed progenitors. While the number of CD34(++)CD45(low) cells increased throughout gestation in parallel with placental mass. However, their density (cells per gram of tissue) reached its peak at 5 to 8 weeks, decreasing more than 7-fold from the ninth week onward. In addition to multipotent progenitors, the ...
Myeloid-derived suppressor cells (MDSCs) are CD11b+Gr1+ cells that induce T-cell hyporesponsiveness, thus impairing antitumor immunity. We have previously reported that disruption of Pak2, a member of the p21-activated kinases (Paks), in hematopoietic stem/progenitor cells (HSPCs) induces myeloid lineage skewing and expansion of CD11bhighGr1high cells in mice. In this study, we confirmed that Pak2-KO CD11bhighGr1high cells suppressed T-cell proliferation, consistent with an MDSC phenotype. Loss of Pak2 function in HSPCs led to (1) increased hematopoietic progenitor cell sensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling, (2) increased MDSC proliferation, (3) decreased MDSC sensitivity to both intrinsic and Fas-Fas ligand-mediated apoptosis, and (4) promotion of MDSCs by Pak2-deficient CD4+ T cells that produced more interferon γ, tumor necrosis factor α, and GM-CSF ...
Primary cells. Peripheral blood and bone marrow samples from patients with newly diagnosed CML-CP, CML-AP, ALL, AML, and t-MDS/AML were obtained from: (a) Stem Cell and Leukemia Core Facility of the University of Pennsylvania, Philadelphia, Pennsylvania, USA; (b) Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna; (c) Princess Margaret Cancer Centre; (d) Department of Hematology, Institute of Hematology and Blood Transfusion, Warsaw, Poland; and (e) Division of Hematopoietic Stem Cell and Leukemia Research, City of Hope National Medical Center. Clinical annotations for these samples are listed in Supplemental Tables 1-4. Samples of normal hematopoietic cells were purchased from Cambrex Bio Science. Lin-CD34+ cells were obtained from mononuclear fractions by magnetic sorting using the EasySep negative selection human progenitor cell enrichment cocktail followed by Human CD34 Positive Selection Cocktail (StemCell Technologies). PLXs containing ...
Enrichment of hematopoietic stem cells is based on the expression of certain surface antigens, such as CD34 and CD133, or on the lack of expression of lineage‐specific antigens
... - This anti-Human Lineage Cocktail is optimized for the detection of human lymphocytes, monocytes, eosinophils, and neutrophils.
Research Objective. We will develop a new agent that can increase the production of hematopoietic stem and progenitor cells and determine how the compound functions. Impact. We aim to develop a method to achieve the highest fold expansion of hematopoietic stem cells from a single unit of cord blood achieved to date increasing the supply of these clinically relevant cells. Major Proposed Activities. ...
We show here that ligation of OX40 Ag, a member of the tumor necrosis factor receptor (TNF-R) family, on activated umbilical cord blood CD4(+) T cells upregulates IL-4 production at priming and thereby promotes their development into effector cells producing high levels of the type 2 cytokines IL-4, IL-5, and IL-13 ...
Over the past few years recombinant human interleukin-2 (IL-2), with or without infusion of in vitro generated lymphokine-activated killer (LAK) cells, has been administered to patients with...
Complete title: Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation with or without Infusion of Off the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients with Hematologic ...
RESULTS: CD44(+) GCSCs showed more cell proliferation and VEGF secretion than CD44-negative cells in vitro, which were accompanied by the high expression of Notch-1 and Hes1 and positively associated with tumor growth (GCSCs vs CD44-negative cells, 2.72 ± 0.25 vs 1.46 ± 0.16, P < 0.05) and microvessel density (MVD) (GCSCs vs CD44-negative cells, 8.15 ± 0.42 vs 3.83 ± 0.49, P < 0.001) in vivo. XTSJ decoction inhibited the viability of both cell types in a dose-dependent manner in vitro. Specifically, a significant difference in the medium- (82.87% ± 6.53%) and high-dose XTSJ groups (77.43% ± 7.34%) was detected at 24 h in the CD44(+) GCSCs group compared with the saline group (95.42% ± 5.76%) and the low-dose XTSJ group (90.74% ± 6.57%) (P < 0.05). However, the efficacy of XTSJ decoction was reduced in the CD44(-) groups; significant differences were only detected in the high-dose XTSJ group at 48 h (78.57% ± 6.94%) and 72 h (72.12% ± 7.68%) when compared with the other CD44- groups (P ...
Mouse anti Human CD163 antibody, clone EDHu-1 recognizes the human CD163 cell surface antigen, a 130-140 kDa glycoprotein expressed by tissue macropha
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the Pub Med ID of your paper to get a coupon. ...
Recombinant Human CD96 Protein (His Tag) product information; Recombinant Human CD96 Protein (His Tag) is available 1 time from supplier adv at Gentaur.com shop
2001 05 22.20858 16 06 45.68 -20 01 22.4 22.0R 01KG76 807 Cd1817 2001 05 22.28897 16 06 45.29 -20 01 21.3 01KG76 807 Cd1817 2001 06 10.02875 16 05 16.38 -19 57 27.3 22.9R 01KG76 304 Cd1817 2001 06 10.10380 16 05 16.05 -19 57 26.3 01KG76 304 Cd1817 2001 08 19.03454 16 02 18.80 -19 50 35.3 21.4R 01KG76 807 Cd7687 2001 08 20.03188 16 02 19.15 -19 50 37.8 01KG76 807 Cd7687 2001 08 21.03938 16 02 19.58 -19 50 40.7 01KG76 807 Cd7687 2002 04 07.29240 16 15 09.97 -20 25 16.3 21.6R 01KG76 807 Cf4617 2002 04 07.38861 16 15 09.68 -20 25 15.6 01KG76 807 Cf4617 2002 05 12.03950 16 12 54.85 -20 19 22.5 01KG76 950 Cf4617 2002 05 12.08513 16 12 54.63 -20 19 21.8 01KG76 950 Cf4617 2002 05 12.13062 16 12 54.41 -20 19 21.3 01KG76 950 Cf4617 2002 05 13.04812 16 12 50.15 -20 19 10.5 01KG76 950 Cf4617 2002 05 13.11749 16 12 49.83 -20 19 09.6 01KG76 950 Cf4617 2002 07 10.99718 16 08 34.27 -20 08 36.4 22.2R 01KG76 304 Cf9823 2002 07 11.20921 16 08 33.59 -20 08 35.0 01KG76 304 Cf9823 2002 07 13.10322 16 08 27.82 -20 08 ...
Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset ...
Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset ...
Serum-free medium for the culture and expansion of hematopoietic cells isolated from human cord blood, bone marrow, or mobilized peripheral blood.
Buy our Human CD2BP2 peptide. Ab45594 is a blocking peptide for ab32899 and has been validated in BL. Abcam provides free protocols, tips and expert support…
Buy our Human CD20 peptide. Ab22803 is a blocking peptide for ab1310 and has been validated in BL. Abcam provides free protocols, tips and expert support for…
SmartDish™ is meniscus-free cultureware that improves the accuracy of manual and automated counting of hematopoietic colony assays.
0054] In important embodiments of the invention, the umbilical cord blood cells are fractionated in order to generate enriched cell populations. As used herein, an enriched cell population is a cell population that has been manipulated in order to increase the frequency of a particular cell type in the population relative to the frequency of that cell type prior to manipulation. It is to be understood that the cell type being enriched is one that existed in the population prior to manipulation, and that enrichment results from the removal of other cell types from the population rather than addition of the cell type of interest. Of particular interest according to the invention are cell populations enriched in CD34+, CD133+, or CD34+/CD133+ cells. CD34 and CD133 are cell surface protein (or markers) that have been identified previously as present on hematopoietic progenitor cells (including on hematopoietic stem cells). As used herein, a CD34+ cell is a cell that expresses CD34 on its cell ...
TY - JOUR. T1 - Polychromatic flow cytometry analysis of CD34+ hematopoietic stem cells in cryopreserved early preterm human cord blood samples. AU - D'Alessio, F.. AU - Mirabelli, P.. AU - Gorrese, M.. AU - Scalia, G.. AU - Gemei, M.. AU - Mariotti, E.. AU - Di Noto, R.. AU - Martinelli, P.. AU - Fortunato, G.. AU - Paladini, D.. AU - Del Vecchio, L.. PY - 2011/1. Y1 - 2011/1. N2 - During the last decades, extended characterizations were performed of human full-term cord blood (hTCB) cells, but little information is available on human early preterm cord blood (hEPCB) hematopoietic stem cells (HSCs). In our study, we analyzed by flow cytometry 19 hEPCB and 17 hTCB samples. First, we observed that the percentage of CD34 PosCD45 Dim cells was higher in hEPCB compared with hTCB and that it decreased during 16th-20th week of pregnancy. Within the CD34 PosCD45 Dim population, we examined the expression of CD29, CD31, CD38, CD90, CD117, CD133, CD135, CD200, CD243, and CD338. We found that CD135 ...
Bone marrow is collected via multiple aspirations from the posterior-superior iliac crest in a sterile environment (usually a surgical operating room) while the patient is under anesthesia. Ideally, HPCs should be collected while the patients marrow is normocellular and uninvolved by the malignancy. Currently, bone marrow HPC collection is rarely, if ever, done for the purpose of autologous transplantation because HPCs can be collected from peripheral blood and engraft more rapidly when collected this way. Hematopoietic progenitor cells are normally infrequent in the blood but are mobilized into the blood during the recovery after chemotherapy and following treatment with granulocyte colony-stimulating factor (G-CSF). Peripheral blood progenitor cells (PBPCs) are collected using apheresis with continuous-flow cell separation. One to four daily apheresis sessions are usually required to achieve the minimal target CD34+ cell dose (at least 2 × 106/kg). The collected PBPCs are subsequently ...
Since monocytes and macrophages that arise during the culture of bone marrow progenitor cells are potential sources of interleukin 6 (IL-6), we investigated whether auto- or paracrine production of this factor is involved in colony formation by normal hematopoietic progenitor cells. We added a polyclonal anti-IL-6 antiserum and a monoclonal anti-IL-6 antibody to cultures of monocyte- and T cell-depleted bone marrow cells. Colony formation was stimulated with granulocyte/monocyte-colony-stimulating factor (GM-CSF), monocyte-CSF, or IL-3. Addition of anti-IL-6 antibody resulted in decreased numbers of monocytic colonies to 40-50% of control values, whereas the numbers of granulocytic colonies were not altered. The inhibitory effect was preserved in cultures of CD34(+)-enriched bone marrow cells. As a second approach, we added a monoclonal antibody directed against the IL-6 receptor to cultures of monocyte- and T cell-depleted bone marrow cells. This antibody almost completely inhibited the growth ...
TY - JOUR. T1 - Widespread nonhematopoietic tissue distribution by transplanted human progenitor cells with high aldehyde dehydrogenase activity. AU - Hess, David A.. AU - Craft, Timothy P.. AU - Wirthlin, Louisa. AU - Hohm, Sarah. AU - Zhou, Ping. AU - Eades, William C.. AU - Creer, Michael H.. AU - Sands, Mark S.. AU - Nolta, Jan A.. PY - 2008/3/1. Y1 - 2008/3/1. N2 - Transplanted adult progenitor cells distribute to peripheral organs and can promote endogenous cellular repair in damaged tissues. However, development of cell-based regenerative therapies has been hindered by the lack of preclinical models to efficiently assess multiple organ distribution and difficulty defining human cells with regenerative function. After transplantation into β-glucuronidase (GUSB)-deficient NOD/SCID/mucopolysaccharidosis type VII mice, we characterized the distribution of lineage-depleted human umbilical cord blood-derived cells purified by selection using high aldehyde dehydrogenase (ALDH) activity with ...
The macrophage colony-stimulating factor-deficient bone marrow stromal cell line OP9, derived from osteopetrotic mice, is known to support hematopoietic stem cell (HSC) expansion as well as hematopoietic differentiation of embryonic stem cells. Coculture of HSC in the OP9 system requires cytokine support to achieve significant cell expansion. Recently, we reported extensive expansion without cell senescence of cord blood (CB)-derived HSC cocultured with OP9 stromal cells for more than 18 weeks with a single cytokine support using human thrombopoietin (TPO). In this study, we evaluated the efficiency of the OP9/TPO coculture system to sustain long-term hematopoiesis of adult, granulocyte colony-stimulating factor mobilized human peripheral blood (PB) CD34(+) cells. Maximum cell expansion was attained during the first 4 weeks of coculture. At the same time, the maximum progenitor cell expansion was demonstrated by the production of colony-forming cells and cobblestone area-forming cells. In contrast to
Acronyms and Abbreviations: AGM, aorta-gonad-mesonephros; BFU-E, burst-forming unit-erythroid; BFU-MK, burst-forming unit-megakaryocyte; CAFC, cobblestone area-forming cell; CAR, CXCL12-abundant reticular; CFC, colony-formingcell; CFU-E, colony-forming unit-erythroid; CFU-GM, colony-forming unit-granulocyte-macrophage; CFU-MK, colony-forming unit-megakaryocyte; CLP, common lymphoid progenitor; CMP, common myeloid progenitor; EBF, early B-cell factor; ECM, extracellular matrix; EGF, epidermal growth factor; EPO, erythropoietin; EPOR, erythropoietin receptor; FAK, focal adhesion kinase; FL, Flt-3 ligand; G-CSF, granulocyte colony-stimulating factor; G-CSF-R, granulocyte colony-stimulating factor receptor; GM-CSF, granulocyte-macrophage colony-stimulating factor; GM-CSF-R, granulocyte-monocyte colony-stimulating factor receptor; GMP, granulocyte-macrophage progenitor; HSC, hematopoietic stem cell; Ig, immunoglobulin; IL, interleukin; IRF4, interferon regulatory factor 4; LEF, lymphoid-enhancer ...

CD34 expression on long-term repopulating hematopoietic stem cells changes during developmental stages<...CD34 expression on long-term repopulating hematopoietic stem cells changes during developmental stages<...

abstract = "The CD34 antigen serves as an important marker for primitive hematopoietic cells in therapeutic transplantation of ... CD34- cells after 16 weeks, indicating that adult Lin-c-Kit+CD34- HSC are the progeny of neonatal CD34-expresssing HSC. Assays ... CD34- cells after 16 weeks, indicating that adult Lin-c-Kit+CD34- HSC are the progeny of neonatal CD34-expresssing HSC. Assays ... CD34- cells after 16 weeks, indicating that adult Lin-c-Kit+CD34- HSC are the progeny of neonatal CD34-expresssing HSC. Assays ...
more infohttps://kyushu-u.pure.elsevier.com/en/publications/cd34-expression-on-long-term-repopulating-hematopoietic-stem-cell

Antigens, CD34 - MeSH - NCBIAntigens, CD34 - MeSH - NCBI

All MeSH CategoriesChemicals and Drugs CategoryBiological FactorsBiomarkersAntigens, DifferentiationAntigens, CDAntigens, CD34 ... All MeSH CategoriesChemicals and Drugs CategoryBiological FactorsAntigensAntigens, SurfaceAntigens, DifferentiationAntigens, CD ... Antigens, CD34. Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date ...
more infohttps://www.ncbi.nlm.nih.gov/mesh?Db=mesh&Cmd=DetailsSearch&Term=%22Antigens,+CD34%22%5BMeSH+Terms%5D

CD34, HPCA1 or Hematopoietic progenitor cell antigen CD34 antibodyCD34, HPCA1 or Hematopoietic progenitor cell antigen CD34 antibody

CD34 protein is involved in differentiating HPCs into certain types of neurons. Also useful for studying endothelial cells, ... Research proven mouse monoclonal CD34 antibody. Excellent marker for hematopoietic progenitors and stem cells. ... CD34 may also stimulate proportions of adult human HSCs to differentiate into full-fledged neurons. This may open new ... In tumors, CD34 is found in alveolar soft part sarcoma, preB-ALL (positive in 75%), AML (40%), AML-M7 (most), ...
more infohttps://www.neuromics.com/MO20026

CD34 (CD34 antigen) - KOMP (Knockout Mouse Project)CD34 (CD34 antigen) - KOMP (Knockout Mouse Project)

OMIM: HEMATOPOIETIC PROGENITOR CELL ANTIGEN CD34; CD34*Gene Ontology: Cd34 *Mouse Phenome DB: Cd34 *UCSC: Chr.1:194,938,821- ... Cd34. CD34 antigen. Gene nomenclature, locus information, and GO, OMIM, and PMID associations are updated daily from MGI ... Researchers interested in Cd34 are also interested* in Pecam1 Efnb2 Angpt1 Krt14 Cd44 Shh Acta2 Tie1 Myb Krt15 ... Ensembl: ENSMUSG16494 (Cd34)*NCBI: 12490, 50886*Vega: OTTMUSG50886*CCDS: 15640, 15640.1, 48490* ...
more infohttps://www.komp.org/geneinfo.php?geneid=33559

Hematopoietic progenitor cell antigen CD34Hematopoietic progenitor cell antigen CD34

Possible adhesion molecule with a role in early hematopoiesis by mediating the attachment of stem cells to the bone marrow extracellular matrix or directly to stromal cells. Could act as a scaffold for the attachment of lineage specific glycans, allowing stem cells to bind to lectins expressed by stromal cells or other marrow components. Presents carbohydrate ligands to selectins ...
more infohttps://pharos.nih.gov/idg/targets/CD34

CD34 ELISA Kits from XpressBio | Biocompare.comCD34 ELISA Kits from XpressBio | Biocompare.com

Compare CD34 ELISA Kits from XpressBio from leading suppliers on Biocompare. View specifications, prices, citations, reviews, ... The ELISA (enzyme-linked immunosorbent assay) is a well-established antibody-based tool for detecting and quantifying antigens ...
more infohttps://www.biocompare.com/pfu/110627/soids/2-230021/ELISA_Kit/ELISA_CD34?vids=106352

CD34 Gene - GeneCards | CD34 Protein | CD34 AntibodyCD34 Gene - GeneCards | CD34 Protein | CD34 Antibody

CD34 Molecule, including: function, proteins, disorders, pathways, orthologs, and expression. GeneCards - The Human Gene ... Hematopoietic progenitor cell antigen CD34) ELISA and Immunotag™ Hematopoietic progenitor cell antigen CD34 ELISA Kit ... View all 43 R&D Systems CD34 (CD34) Products. *View all R&D Systems CD34 (CD34) Proteins and Enzymes*Recombinant Human CD34 ... GeneCards Summary for CD34 Gene CD34 (CD34 Molecule) is a Protein Coding gene. Diseases associated with CD34 include Spindle ...
more infohttps://www.genecards.org/cgi-bin/carddisp.pl?gene=CD34&keywords=GH01J207913&prefilter=genomic_location

CD34 Gene - GeneCards | CD34 Protein | CD34 AntibodyCD34 Gene - GeneCards | CD34 Protein | CD34 Antibody

CD34 Molecule, including: function, proteins, disorders, pathways, orthologs, and expression. GeneCards - The Human Gene ... Hematopoietic progenitor cell antigen CD34) ELISA and Immunotag™ Hematopoietic progenitor cell antigen CD34 ELISA Kit ... GeneCards Summary for CD34 Gene CD34 (CD34 Molecule) is a Protein Coding gene. Diseases associated with CD34 include Spindle ... Animal Models for CD34 Gene. MGI Knock Outs for CD34:. * Cd34 Cd34,tm1Szk, ...
more infohttps://www.genecards.org/cgi-bin/carddisp.pl?gene=CD34&keywords=central+nervous+system+angiosarcoma&prefilter=diseases

Recombinant Human CD34 protein (ab182830) | AbcamRecombinant Human CD34 protein (ab182830) | Abcam

Buy our Recombinant Human CD34 protein. Ab182830 is a protein fragment produced in Escherichia coli and has been validated in ... CD34 molecule. *CD34_HUMAN. *Cluster designation 34. *Hematopoietic progenitor cell antigen CD34 ...
more infohttp://www.abcam.com/recombinant-human-cd34-protein-ab182830.html

Multi-color CD34⁺ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post...Multi-color CD34⁺ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post...

CD34, CD38, CD117, and CD123; aberrant expression of lymphoid or mature myelomonocytic antigens on CD34(+) myeloblasts; and ... Multi-color CD34⁺ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post ... With recent advances in multi-color flow cytometry immunophenotypic analysis, a CD34(+) progenitor-focused 7-color assay was ... a core panel of markers was selected for final assessment that included increased total CD34(+) myeloblasts; decreased stage I ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/22626984?dopt=Abstract

CD34 Antibody, FITC (Monoclonal, MEC14.7)
		        
	CD34 Antibody, FITC (Monoclonal, MEC14.7)

CD34 Monoclonal Antibody, FITC conjugate from Invitrogen for Western Blot, Immunohistochemistry (Frozen), Immunohistochemistry ... Protein Aliases: CD34; CD34 antigen; cluster designation 34; Hematopoietic progenitor cell antigen CD34; Mucosialin; RP11- ... CD34 is a monomeric cell surface antigen with a molecular mass of approximately 110 kD that is selectively expressed on human ... Cite CD34 Monoclonal Antibody (MEC14.7), FITC. The following antibody was used in this experiment: CD34 Monoclonal Antibody ( ...
more infohttps://www.thermofisher.com/antibody/product/CD34-Antibody-MEC14-7-Monoclonal/MA5-17829

CD34 (human)CD34 (human)

Home > Protein > CD34 human. mouse. rat. New Protein Search:. Hematopoietic progenitor cell antigen CD34 ...
more infohttps://www.phosphosite.org/proteinAction.action?id=4561&showAllSites=true

Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication -...Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication -...

Antigens, CD34. abacavir. Treatment Naive. Additional relevant MeSH terms: Infection. HIV Infections. Lentivirus Infections. ...
more infohttps://clinicaltrials.gov/show/NCT00006578?order=378

POVEZANOST POJAVE PERITUMORALNIH PUKOTINA U DUKTALNOM INVAZIVNOM KARCINOMU DOJKE S MIOFIBROBLASTIČNOM REAKCIJOM STROMEPOVEZANOST POJAVE PERITUMORALNIH PUKOTINA U DUKTALNOM INVAZIVNOM KARCINOMU DOJKE S MIOFIBROBLASTIČNOM REAKCIJOM STROME

There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions. J ... Barth PJ, Schenck zu Schweinsberg T, Ramaswamy A, Moll R. CD34+ fibrocytes, alpha-smooth muscle antigen-positive myofibroblasts ... Figure 3 Two cases (left and right rows of pictures) of stromal cell expression of CD34 and vimentin. Healthy breast tissue ... Nasuprot tomu, stroma svih invazivnih i duktalnih karcinoma dojke in situ nije sadržavala fibroblaste pozitivne na CD34. Većina ...
more infohttps://hrcak.srce.hr/index.php?show=clanak&id_clanak_jezik=302501

Intra-coronary Infusion of Bone Marrow Derived Autologous CD34+ Selected Cells in Patients With Acute Myocardial InfarctionIntra-coronary Infusion of Bone Marrow Derived Autologous CD34+ Selected Cells in Patients With Acute Myocardial Infarction

Antigens, Cd34. Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date ... spontaneous improvement in cardiac function without CD34+cell infusion. ...
more infohttps://www.bioportfolio.com/resources/trial/108249/Intra-coronary-Infusion-of-Bone-Marrow-Derived-Autologous-CD34-Selected-Cells-in.html

Vascular leak is a central feature in the pathogenesis of systemic sclerosis.Vascular leak is a central feature in the pathogenesis of systemic sclerosis.

Antigens, CD34 / analysis. Capillary Leak Syndrome / pathology*. Edema / pathology. Endothelium, Vascular / pathology*, ... Lower CD34 staining was seen in SSc compared to healthy controls (0.32% ± 0.22% vs 1.31% ± 0.34%; p , 0.0001) and within the ...
more infohttp://www.biomedsearch.com/nih/Vascular-Leak-Central-Feature-in/22660809.html

MEDLINE - Resultado p gina 1
	MEDLINE - Resultado p gina 1

0 (Antigens, CD34); 0 (BCR-ABL1 fusion protein, human); 0 (Biomarkers, Tumor); 0 (IL2RA protein, human); 0 (Interleukin-2 ... Whereas normal CD34 /CD38 BM stem cells display only low amounts of CD25 or lack CD25 altogether, CD34 /CD38 LSCs express CD25 ... Ant genos CD34/metabolismo. C lulas da Medula ssea/metabolismo. Seres Humanos. Glicoprote nas de Membrana/metabolismo. C lulas- ... BACKGROUND: Rh phenotype is an extremely rare condition characterized by no expression of Rh antigens at the surface of red ...
more infohttp://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&nextAction=lnk&base=MEDLINE&lang=p&format=detailed.pft&indexSearch=EX&exprSearch=D12.776.395.550

Intraosseous epithelioid hemangioendothelioma of the mandible: a case report with an immunohistochemical study.Intraosseous epithelioid hemangioendothelioma of the mandible: a case report with an immunohistochemical study.

Antigens, CD34 / analysis. Female. Hemangioendothelioma, Epithelioid / chemistry, pathology*, surgery. Humans. Lectins / ... 0/Antigens, CD34; 0/Lectins; 0/Neoplasm Proteins; 0/Plant Lectins; 0/Ulex europaeus lectins; 0/Vimentin; 0/von Willebrand ... and CD 34, but not against keratin, epithelial membrane antigen (EMA) or S-100 protein (S100). The proliferating cell nuclear ... factor VIII-related antigen (F8RA), Ulex europaeus agglutinin type 1 lectin (UEA-1), ...
more infohttp://www.biomedsearch.com/nih/Intraosseous-epithelioid-hemangioendothelioma-mandible-case/10226947.html

Patent US20070042017 - Medical device with coating that promotes endothelial cell adherence and ... - Google PatentsPatent US20070042017 - Medical device with coating that promotes endothelial cell adherence and ... - Google Patents

... bind to and/or interact with a progenitor cell surface antigen to immobilize the cells at the surface of the device. The ... In one embodiment, monoclonal antibodies reacting with the endothelial cell surface antigen CD34 are used. Anti-CD34 monoclonal ... CD34, Thy-1, Thy-2, Muc-18 (CD146), CD30, stem cell antigen-1 (Sca-1), stem cell factor (SCF or c-Kit ligand), CD133 antigen, ... are photomicrographs of HUVECs attached to the CMDx and anti-CD34 antibody (4A); gelatin and anti-CD34 antibody (4B); bare ...
more infohttp://www.google.ca/patents/US20070042017

Giant Cell AngiofibromaGiant Cell Angiofibroma

... for vimentin and CD 34 but negative for any other antigens, including Factor VIII-related antigen, desmin, alpha smooth muscle ... Cells express human progenitor cell antigen CD34 and vimentin. One case in the buccinator fascia was also noted by the authors ... Tumor cells were strongly positive for vimentin and CD34 and were negative for other antigens. After excision, there has been ... Positive for vimentin, CD34, CD99, and mostly for bcl-2. Negative for muscle specific actin, desmin, CD31, CD117 (c-kit), and ...
more infohttp://www.thedoctorsdoctor.com/diseases/angiofibroma_giantcell.htm

CD34 (human)CD34 (human)

Names/Synonyms: CD34; CD34 antigen; CD34 molecule; Hematopoietic progenitor cell antigen CD34 ... CD34 Possible adhesion molecule with a role in early hematopoiesis by mediating the attachment of stem cells to the bone marrow ... Belongs to the CD34 family. 2 isoforms of the human protein are produced by alternative splicing. Note: This description may ...
more infohttps://www.phosphosite.org/proteinAction.action?id=4561

Anti-CD34 antibody (PE/Cy7 ®) [4H11] | AbcamAnti-CD34 antibody (PE/Cy7 ®) [4H11] | Abcam

Anti-CD34 antibody conjugated to PE/Cy7 ® [4H11] validated for Flow Cyt and tested in Human. Immunogen corresponding to the ... CD34 molecule antibody. *CD34_HUMAN antibody. *Cluster designation 34 antibody. *Hematopoietic progenitor cell antigen CD34 ... Anti-CD34 antibody [4H11], prediluted (Allophycocyanin) (ab155377) *Anti-CD34 antibody [4H11], prediluted (Alexa Fluor® 488) ( ... Anti-CD34 antibody [4H11], prediluted (PE/Cy7 ®). See all CD34 primary antibodies. ...
more infohttps://www.abcam.com/cd34-antibody-4h11-prediluted-pecy7-ab155358.html

HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. | CureHunterHIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. | CureHunter

Antigens, CD34. *Antiretroviral Therapy, Highly Active. *Graft Survival. *Humans. *Longitudinal Studies. *Lymphoma, AIDS- ...
more infohttp://www.curehunter.com/public/pubmed15781340.do

GO Gene ListGO Gene List

Cd34. CD34 antigen. NM_001111059. NM_133654. Gene Info. Cfh. Complement component factor h. NM_009888. Gene Info. ...
more infohttps://cgap.nci.nih.gov/Genes/GoGeneQuery?PAGE=1&ORG=Mm&GOID=1901681

Fc gamma RIIIA/CD16a Antibody (DJ130c) (NB100-64346): Novus BiologicalsFc gamma RIIIA/CD16a Antibody (DJ130c) (NB100-64346): Novus Biologicals

CD34 antigen. Specificity. NB100-64346 recognizes human CD16, a 50-65kD cell surface molecule, which is the low affinity ... For IHC-Paraffin: This product requires antigen retrieval using heat treatment prior to staining of paraffin sections; sodium ... I would require a CD16 Recombinant Protein as an antigen and Anti-Human IgG (Fc specific) as a secondary antibody as I am ...
more infohttps://www.novusbio.com/products/fc-gamma-riiia-cd16a-antibody-dj130c_nb100-64346
  • With recent advances in multi-color flow cytometry immunophenotypic analysis, a CD34(+) progenitor-focused 7-color assay was developed and tested in this clinical setting. (nih.gov)